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ABSTRACT 
 This dissertation comprises identifying the structural determinants of binding 
selectivity as demonstrated in three systems.  
The first system involves the structure determination of Keap1-small molecule fragment 
complexes to locate binding surfaces.  The second system involves the structural 
determination of a NEMO/IKKbeta complex to serve as a platform for future fragment 
binding validation studies. The third system involves the structural investigation of a 
bacterial phosphoglycosyltransferase found in Campylobacter concisus to find the active 
site. Keap1 binding of Nrf2 is a regulatory mechanism to inhibit the transcription 
factor activity of Nrf2 to upregulate Nucleoporin p62 (p62). Nucleoporin p62 is a 
regulator of tau protein aggregates in Alzheimer's disease. The determination of binding 
hot spots in the Keap1 active site could serve as a starting point for the development of 
inhibitors as a treatment method for Alzheimer’s disease. To achieve this, I have 
developed a crystal form of Keap1 that allows for fragment-based study of binding in the 
active site via small molecule fragment screening and X-ray crystallography. Analysis of 
collected data has resulted in the solution of four structures, one containing a peptide 
fragment and three containing small molecule fragments that occupy a region of binding 
  vii 
within the Keap1 active site, demonstrating the utility of the crystal form and affording 
information on binding hot spots. 
 Nuclear factor κ-light-chain enhancer of activated B cells (NF-κB) is a 
transcription factor and has been linked to cancer, inflammation, and immune 
dysfunction. The enzyme complex IκB kinase (IKK) is a regulator of NF-κB and consists 
of three subunits: IKK-α, IKK-β, and NEMO. If NEMO activity is abrogated, IKK is 
unable to activate NF-κB, making it a promising therapeutic target. My research has 
found crystallization conditions and performed trials of phase determination on an N-
terminal IKKβ-binding construct of NEMO containing previously uncharacterized 
regions of this protein. 
 Glycosylation is a commonly occurring post-translational modification that 
affects a number of processes including protein folding, trafficking, cell-cell interactions 
and host immune response.  The phosphoglycosyl transferase PglC is an essential part of 
the Campylobacter glycosylation pathway and a possible antibacterial target.  My 
research determined the crystallization conditions and has developed complexes and 
protein constructs for phase determination of this single-pass transmembrane protein and 
will in the future provide a platform for structure-based inhibition of this protein. 
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CHAPTER ONE 
1.1 Keap1/Nrf2 Introduction and Literature Review 
1.1.1 Redox Homeostasis and Cellular Response to Oxidative Stress 
 
 Cells have the ability to upregulate cytoprotective enzymes in response to reactive 
oxygen and nitrogen species.  Phase II detoxifying enzymes are under transcriptional 
control and transcription factors play a large role in mediating the cytoprotective 
response. A transcription factor, nuclear factor erythroid 2-related factor 2 (Nrf2), that 
upregulates antioxidant response elements has been identified based on expression 
profiles. (1)  A binding partner of Nrf2 has been identified through a yeast two-hybrid 
system named Kelch-like ECH-associated protein 1 (Keap1).(2) Keap1 is inactivated by 
reactive oxygen species, which indicates that it could be responsible for regulation of 
Nrf2’s response to those elements.(3, 4) Keap1 knockout mice have aberrant gene 
expression; hyperkeratosis results in death postnatally and is associated with upregulation 
of squamous cell genes. Keap1 knockout mice that also lack Nrf2 do not possess the 
same aberrant gene expression and this suggests that the pathology came from a lack of 
Keap1 regulation of Nrf2. (5) Based on these studies, it is evident that regulation in the 
Keap1-Nrf2 interaction is important for organism survival. 
1.1.2 Keap1/Nrf2 in Biological Function 
 Dysregulation of Nrf2 transcription can lead to pathology from both over-
activation and under-activation. Keap1 mutations that render the protein unable to 
regulate Nrf2 have been characterized in lung cancer, breast cancer and gallbladder 
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cancer indicating that increased chemoresistance can result from overactivation of the 
Nrf2 pathway. (6–12) Upregulation of the Nrf2 pathway results in expression of 
cytoprotective enzymes that can allow cancer cells to survive chemotherapeutics that 
would normally trigger apoptosis.  A phosphorylated motif of p62, a competitor of Nrf2 
for Keap1 binding, is found to bind Keap1 and aggregate in neurofibrillary tangles. The 
p62 protein is found in higher concentrations in the brain tissue of Alzheimer’s disease 
patients compared to brain tissue from control patients, indicating that Nrf2 is activated in 
response to the progression of Alzheimer’s disease. (13) Inhibition of Keap1 and 
therefore Nrf2 activation could assist in this process and be a useful target for 
neurodegenerative disease treatment.  Specifically dimethyl fumarate, a Keap1 inhibitor, 
has been approved as a therapeutic for multiple sclerosis. (14, 15) Other binding partners 
of Keap1 have been identified, including Fetal Alz-50 clone 1 (Fac1), phosphoglycerate 
mutase 5 (PGAM5), p62, IKKβ, Wilm’s tumor gene on X chromosome protein complex 
(WTX), partner and localizer of breast cancer type 2 susceptibility protein (PALB2), and 
dipeptidyl peptidase 3 (DPP3). (16–22) Pathology resulting from disruption of the 
Keap1/Nrf2 interaction as well as the number of other binding partners of Keap1 
indicates that this transcription factor pathway is both vital and complex. 
1.1.3 Structure and Function of Keap1/Nrf2  
 Nrf2 is a 66 kDa protein that belongs to the basic leucine zipper family (bZIP).  It 
was first identified as a binding partner for proteins in the AP1 family of proteins and to 
NF-E2. (23).  Nrf2 consists of six Nrf2-ECH homology domains (Neh) domains 
identified as Neh1 through Neh6 (Figure 1.1) named for their homology with the 
  
3 
erythroid cell-derived protein with Cap’N’Collar (CNC) homology (ECH).  Neh1 
contains a basic leucine zipper domain and a region homologous to the CNC family of 
proteins.(23)  The N-terminus of the protein contains the Neh2 domain while the C-
terminus contains Neh3.  There are two acidic domains, Neh4 and Neh5, as well as a 
serine-rich conserved region, Neh6.  Two experiments indicate that Nrf2 is regulated by a 
binding partner through the Neh2 domain. Transfection of a deletion mutant of Neh2 
which lacked the regulatory binding region results in Nrf2 pathway activation, indicating 
that the regulatory mechanism is not able to affect a mutant without the Neh2 domain.  
The other experiment that indicates binding partner regulation of Nrf2 is co-transfection 
with a decoy Neh2 domain, which competes with the Nrf2 binding partner and also 
results in an increased activation of the Nrf2 pathway. (2) 
 In 1999, Itoh et al. used the Nrf2 domain Neh2 to identify a binding partner, 
Keap1, in a yeast two-hybrid system using mouse cDNA.  Homology to both the fruit fly 
protein Kelch as well a previously uncharacterized human protein was reported along 
with its discovery.(2)  The localization of Keap1 in the cytosol is confirmed by 
visualization of Keap1-GFP fusion protein expressed in 293T cells.(2)  It was then 
proposed that Keap1 regulates Nrf2 activity by sequestration in the cytosol but this was 
later refuted (vide infra). (2)  
 The electrophilic agents, diethylmaleate and catechol, have been shown to 
interfere with the ability of Keap1 to inhibit Nrf2.  While the exact mechanism of 
interference is not yet known, a suggested pathway is through modification of thiol 
groups present on cysteines in Keap1 that result in a conformation change that disrupts 
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the interaction between Keap1 and Nrf2.(24)  Diethylmaleate and catechol covalently 
modify cysteine residues via S-alkylation which mimics the same disruption of binding 
that would occur by the action of reactive oxygen species in a cellular environment.In the 
absence of these agents, Nrf2 is retained in the cytosol but in their presence Nrf2 is 
localized in the nucleus.(25)  
 Keap1 consists of three main domains (see Figure 1.1) that each play a different 
role in its function: the Bric-a-Brac/Tramtrack/Broad-complex domain (BTB), the 
intervening domain (IVR), and the Kelch domain.(3). The BTB domain is the region of 
dimerization between molecules of Keap1, determined by disruption caused by a S104A 
mutation.(26) The intervening region domain(IVR) connects the BTB and Kelch domain 
and contains redox-sensitive residues that inactive the ability of Keap1 to degrade 
Nrf2.(3) The Kelch domain binds to Nrf2 through the Neh2 domain at the sites of two 
separate motifs defined by their amino acid sequence: ETGE (residues 76 to 84) and 
DLG (residues 17-36). (27) 
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Figure 1.1: Domain boundaries and residue numbers of human Nrf and Keap1.  
Domains of Nrf2 are labeled Neh1-Neh6.  The Broad-complex/Tramtrack/Bric-a-Brac (BTB) domain, 
intervening region (IVR) and the Kelch domain are labeled on the Keap1 schematic. The Neh2 domain of Nrf2 
contains the ETGE (76-84) and DLG (17-36) motifs responsible for binding to Keap1. 
 The crystal structure of mouse Keap1 kelch domain gave insight into the overall 
structure, which consists of six kelch repeats forming a symmetric 6-bladed β-propeller 
structure with a central channel, as shown in Figure 1.2 Each blade consists of 4 
antiparallel β-strands with the first and last blade connected using a C-terminal strand 
closure mechanism.  The blades are linked together through conserved Tyr/Trp residues 
that help to form the hydrophobic core of the protein.  Mutation of a proline residue to 
serine at residue 383 reduces binding of Nrf2 which indicates the location of a possible 
Nrf2 binding pocket. (28) A high-resolution structure of the mouse kelch domain of 
Keap1 identifies a network of conserved water molecules between conserved tyrosines 
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and side chain hydroxyl groups of tryptophan residues (29).  A bridge of two waters 
spans adjacent blades, connecting a backbone amide of tryptophan to what is usually a 
proline in the D-A loop connecting the blades. (29) Structures have been determined of 
the mouse Keap1 kelch domain co-crystallized with peptides containing sequence motifs 
corresponding to two separate sites of the Neh2 domain of Nrf2, the ETGE motif and the 
DLG motif. These structures support the location of the Nrf2 binding pocket and identify 
key binding interactions in the Neh2 domain. (6) A summary of the existing crystal 
structures of both mouse and human Kelch binding domain and ligands is given in Table 
1.1.  While many crystal structures exist and serve as a starting point for structural 
analysis of binding, no small molecule fragment cocrystal structures are yet available in 
the PDB. 
 
Table 1.1: Table of Keap1 Structures available from the PDB  
PDBID/ 
Identifier 
Organism Description 
1X2J MOUSE First Structure of mouse Keap1 
1X2R MOUSE ETGE 9mer 
2DYH MOUSE DLG 15mer 
2Z32 MOUSE prothymosin alpha 
3ADE MOUSE sequestosome-1/p62 
3WDZ MOUSE phosphorylated p62 
3WN7 MOUSE DLG 34mer 
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1ZGK HUMAN First structure of human Keap1 
2FLU HUMAN ETGE 16mer 
3VNG HUMAN 
2-(3-((3-(5-(furan-2-yl)-1,3,4-oxadiazol- 2-
yl)ureido)methyl)phenoxy)acetic acid 
4IN4 HUMAN 
(2-({5-[(2,5-dimethylbenzene)sulfonyl]-6-oxo-1,6-
dihydropyrimidin-2-yl}sulfanyl)-N-[2-
(trifluoromethyl)phenyl]acetamide) 
4IQK HUMAN (N,N’-1,4-naphthalenediylbis(4-methoxybenzenesulfonamide)) 
3ZGD HUMAN First Structure of Keap1 for Ligand Soaks 
3ZGC HUMAN ETGE 7mer (cyclized) 
4IFL HUMAN ETGE 16mer 
4L7B HUMAN 
(1S,2R)-2-{[(1S)-1-[(1,3-dioxo-1,3-dihydro- 2H-isoindol-2-
yl)methyl]-3,4-dihydroisoquinolin- 2(1H)-
yl]carbonyl}cyclohexanecarboxylic acid 
4L7C HUMAN 
2-{[(1S)-2-{[(1R,2S)-2-(1H-tetrazol-5-yl)cyclohexyl]carbonyl}- 
1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}- 1H-isoindole-
1,3(2H)-dione 
4L7D HUMAN 
(1S,2R)-2-{[(1S)-5-methyl-1-[(1-oxo-1,3-dihydro- 2H-isoindol-
2-yl)methyl]-3,4-dihydroisoquinolin- 2(1H)-
yl]carbonyl}cyclohexanecarboxylic acid 
4N1B HUMAN 
(1S,2R)-2-{[(1S)-1-[(1-oxo-1,3-dihydro-2H- isoindol-2-
yl)methyl]-3,4-dihydroisoquinolin- 2(1H)-
yl]carbonyl}cyclohexanecarboxylic acid 
KEAP1 HUMAN Structure of Keap1 with fully accessible active site 
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KEAP1-
ETGE HUMAN ETGE peptide soaked 
KEAP1-
P2C HUMAN P2C fragment 
KEAP1-
HPP HUMAN HPP fragment 
KEAP1-
P1A8 HUMAN P1A8 fragment 
 
Figure 1.2: Ribbon diagram showing the structure of Keap1.  
Kelch Domain painted with color ramping from blue to red (from N to C-terminus). The blades of the domain 
are numbered and strands lettered. 
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 Characterization of the Nrf2 Neh2 domain’s binding motifs is important to the 
understanding of the nature of the binding interaction. Isothermal titration calorimetry 
(ITC) of variants bearing alanine mutations indicates that acidic residues in peptides 
corresponding to binding regions of Keap1 contribute the largest differences in binding 
energy.  In Nrf2, mutations of ETGE (Q26A, D27A, D29A) and DLG (D77A, E79A) 
have been found to decrease the degradation of Nrf2 which led to the hypothesis that 
orientation of both motifs in the binding pocket is crucial in aligning Nrf2 for proper 
degradation. (30).  A thermodynamic analysis of DLG peptide binding indicates that 
DLG binding is driven by both enthalpy and entropy, whereas the binding of ETGE 
peptide is purely enthalpy driven.(31)  Surface plasmon resonance binding experiments 
indicates that DLG follows a fast-association, fast-dissociation model while the ETGE 
peptide has a slow binding step that leads to a stable conformation.  The minimum 
interaction region of the Nrf2-DLG motif has been determined by pull-down assay and 
differential scanning fluorimetry.(31) The characterization of binding determinants of 
these peptides is an important step in the process of designing an inhibitor to block these 
determinants.  
 Keap1 has several sulfhydryl groups in the IVR domain and it has been 
demonstrated that these groups function as redox sensors for the cell which inactivate the 
ability of Keap1 to inhibit Nrf2 (3, 32). C151 is identified as a unique residue modified 
by oxidative stress (33). Keap1 actively targets Nrf2 for degradation via ubiquitin-
mediated proteasomal degradation instead of passively sequestering it in the cytosol as 
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previously supposed, leading to the identification of Keap1's role as part of a cullin E3 
ubiquitin ligase complex. (33) 
1.1.4 Cullin E3 Ubiquitin Ligase Complex Structure 
 Keap1 is found to associate with cullin proteins and is identified as forming a 
Cul3 E3 ubiquitin ligase complex as shown in Figure 2.3.  It is the ubiquitination of seven 
lysine residues (K45, 51, 53, 54, 57, 64, 68) in Nrf2 by this complex that mark it for 
degradation.(34) Mutation of the ETGE motif results in an increased half-life of Nrf2, 
indicating that regulation occurs through degradation. Keap1 interacts with Cul3 via the 
IVR domain.(35) . Nrf2 does not associate with the Cul3 complex in the absence of 
Keap1. Furthermore, Cul3 regulates Nrf2 expression, indicating that the Cul3 E3 
ubiquitin ligase complex is the key regulator of Nrf2 expression.  (36) Mutation of the 
Cul3 N-terminus or the BTB domain of Keap1 disrupt the E3 ubiquitin ligase complex 
association, suggesting interaction of those domains. (37) Prothymosin α (PTMα) 
interacts with the Cul3 E3 ubiquitin ligase complex and enables import of the complex 
into the nucleus where it can then degrade nuclear Nrf2 and reduce upregulation of the 
antioxidant response.(38)  PTMα was confirmed to occupy the same binding pocket as 
the ETGE and DLG motifs of Nrf2 by the solution of a co-crystal structure.(39) A 
schematic representing the cellular activity of the Keap1 in ubiquitin ligase complex is 
summarized in Figure 1.4 
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Figure 1.3: E3 Ubiquitin Ligase Complex  
Complex is showing Cul3 association with Keap1 through the BTB dimerization domain and binding of Nrf2 
through recognition of the Kelch domain binding motifs. 
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Figure 1.4: Cellular pathway of Keap1/Nrf2. 
 In the presence of reactive oxygen species, Keap1 becomes unable to ligate ubiquitin to Nr2 which results in 
translocation of Nrf2 to the nucleus where it forms a heterodimer with the Maf family member and binds to the 
ARE region to upregulate cytoprotective gene expression.  In the absence of this signal, Nrf2 binds to Keap1, is 
polyubiqtuitinated and degraded by the proteasome 
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1.1.5 Proposed Interaction Mechanisms 
 A two-site mechanism for the interaction of Nrf2 and Keap1 has been proposed, 
using NMR and ITC data to show that the stoichiometry of the Keap1:Nrf2 interaction is 
2:1 and that the ETGE and DLG motifs interact with the same site of Keap1.  In this 
mechanism, Keap1 dimerizes through the BTB domain.  The Neh2 domain of Nrf2 
interacts with each monomer of the Keap1 Kelch domain through the ETGE and DLG 
motifs in the Neh2 domain of Nrf2.  The central α helix of Neh2 spans the gap between 
the two Keap1 monomers.(40) An alternative mechanism for Nrf2 activation has also 
been proposed where Keap1 undergoes a conformational change in the presence of 
reactive oxygen species into a closed conformation in which Nrf2 is no longer 
ubiquitinated. (41) Both of these mechanisms are illustrated in Figure 2.5. 
 
Figure 1.5: The two proposed mechanisms of inhibition of Keap1. 
In mechanism A, a conformational change in Keap1 disrupts the Cul3 complex association and prevents Nrf2 
from being ubiquitinated and degraded. In mechanism B, Keap1 undergoes a conformational change that 
disrupts orientation of the Nrf2 molecule in a way that does not allow ubiquitination. 
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1.1.6 Inhibitors of Keap1/Nrf2 binding 
 The structural information available for the Keap1/Nrf2 active site interaction 
provides many useful pieces of information that can be applied in the structure-based 
design of an inhibitor.  A number of structures of small molecule ligands that bind in the 
active site of Keap1 have been deposited in the Protein Data Bank (PDB) (see Table 1.1). 
The largest of the small molecules are compounds in the benzenesulfonyl-pyrimidone 
and N-phenyl benzenesulfonamide class that have been identified as non-covalent binders 
of Keap1 by two-dimensional fluorescence intensity distribution analysis, nuclear 
magnetic resonance (NMR), native mass spectrometry and X-ray crystallography with 
IC50 measurements of 118 µM and 2.7µM respectively. (42)  In addition to small 
molecules, a number of Keap1 structures have been reported that are co-crystallized in 
the presence of peptides (see Table 1.1).  In addition to peptides corresponding to the 
ETGE and DLG motifs mentioned earlier, a serine-phosphorylated peptide based on the 
binding motif from p62 that has increased binding affinity when phosphorylated has been 
reported.(43)  A crystallization condition for human Keap1 more suitable for ligand-
soaking experiments has been reported indicating that there will likely be an increase in 
the amount of structural information available for this interaction. (44)  Structure-based 
inhibitor design is an attractive strategy for a target with a large amount of reported 
structural data. 
 Protein-protein interfaces, like the interface between Keap1 and Nrf2, are 
generally large and usually lack the well-defined pocket associated with a typical enzyme 
active site.  However, within these interaction sites are a few amino acids, or hotspots, 
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that contribute a large portion of the binding energy for the protein-protein 
interaction.(45)  Fragment-based drug discovery is a strategy used to uncover those 
hotspots by exploring chemical space with a variety of different small molecule 
fragments with a lower affinity for binding.  Fragment based screening requires an initial 
screening method that can investigate a large number of fragments for possible binding 
and a validation method that can confirm fragment binding in greater detail and uncover 
the associated binding hotspot.  Herein, for Keap1, a fluorescence-based thermal shift 
assay is used as the initial high throughput method with the commercially available 
Zenobia fragment library as well as in-house library of compounds available through the 
Boston University Center for Molecular Discovery.(46) The thermal shift assay has a low 
sensitivity level(47) and therefore requires a higher fragment concentration, the high 
throughput format and its success in protein-protein interface targets make it suitable for 
this project.(48)  For validation, the atomic resolution of X-ray crystallography allows for 
detailed visualization of not only initial fragment binding, but of the derivatized fragment 
throughout the iterative process as the fragment is optimized.  Fragment hits can be 
improved through growing a fragment to make use of interactions neighboring the initial 
binding site or by linking separate fragments together to make use of multiple binding 
hotspots. Combining fragment data with peptide binding at the protein-protein interaction 
site of RAD51 and BRCA2 led to the development of a fragment-peptide molecule.(49) 
The validation methods for the Keap1-Nrf2 fragment study will include data available in 
the protein data bank (PDB) in determining hotspots and directing compound 
optimization. 
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 A crystal structure showing a covalent inhibitor in complex with a cysteine 
residue within the BTB domain of Keap1 highlights another route for protein-protein 
interface (PPI) inhibition by targeting the dimerization and interaction with the Cul3 
complex. (50) However, disruption of this interaction requires modification of cysteine 
residues which could have many off-target and toxic effects.  The IVR region of Keap1 
has not been crystallized to date. Our strategy is to develop a noncovalent inhibitor that 
uses a fragment based approach to investigation of binding at specific hot spots in the 
active site of Keap1 using a construct of the Kelch domain of Keap1 amenable for 
soaking experiments.(44) 
1.2 Materials and Methods 
1.2.1 Cloning and Mutagenesis 
 Construct of the Keap1-ATA mutant was prepared by Stefan Jehle (Allen Lab, 
BU).  Codon-optimized DNA corresponding to residues 312 to 623 of Keap1 was 
synthesized by Genewiz in a pUC57 vector.  The sequence was then subcloned into a 
p15b vector for expression. The construct was designed to use a T7 promoter site and to 
allow for isopropyl β-D-1-thiogalactopyranoside (IPTG)-induced overexpression of a N-
terminal His6 tag followed by a TEV cleavage site preceding the sequence corresponding 
to the Kelch domain of Keap1.  Using the Agilent Quikchange mutagenesis method, 
modifications were made to the sequence of Keap1 to mutate glutamate residues 540 and 
542 to alanine and cysteine residues 319, 613, and 622 to serine.  The cysteine to serine 
mutations were added to improve the expression and solubility of the construct. 
Information about this construct is summarized in Table 1.2 
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Table 1.2: Macromolecule production data 
Organism
  
Homo sapiens 
Expression 
vector 
P15b 
Expression 
host 
SoluBL21 
Complete 
amino acid 
sequence of 
the construct 
produced 
MGSSHHHHXHSSGGENLYFQGHMKPTQVMP(S)RAPKVG
RLIYTAGGYFRQSLSYLEAYNPSDGTWLRLADLQVPRSG
LAGCVVGGLLYAVGGRNNSPDGNTDSSALDCYNPMTNQ
WSPCAPMSVPRNRIGVGVIDGHIYAVGGSHGCIHHNSVE
RYEPERDEWHLVAPMLTRRIGVGVAVLNRLLYAVGGFD
GTNRLNSAECYYPERNEWRMITAMNTIRSGAGVCVLHN
CIYAAGGYDGQDQLNSVERYDV(A)T(A)TWTFVAPMKH
RRSALGITVHQGRIYVLGGYDGHTFLDSVECYDPDTD 
TWSEVTRMTSGRSGVGVAVTMEP(S)RKQIDQQN(S)T 
1.2.2 Protein Production 
 The plasmid was transformed into SoluBL21 cells and expressed at an OD600 of 
0.6 with 1 mM IPTG overnight at 20 °C in Lysogeny Broth (LB) media containing 100 
μg/mL carbenecillin.  The cells were then harvested by centrifugation at 10,000 g for 10 
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minutes at 4 °C and resuspended in a lysis buffer of 50 mM Tris pH 8.0, 500 mM NaCl, 
20 mM imidazole, 2.5mM dithiothreitol (DTT), 1 mM phenylmethanesulfonylfluoride 
(PMSF) and 1 tablet SigmaFast protease inhibitor.  Cells were lysed using a 
microfluidizer at 18000 psi and the cellular debris separated by centrifugation at 38000 g 
for 30 minutes.  The supernatant was applied to a 5 mL HisTrap FF column using an 
AKTA FPLC.  The column was washed with 20 column volumes (CV) of lysis buffer, 20 
CV of lysis buffer plus 50 mM imidazole and then eluted in 5 mL fractions with 50 mM 
Tris pH 8.0, 500 mM imidazole, and 5 mM DTT.  Fractions containing protein were 
pooled and dialyzed into 25 mM Tris pH 8.0, 50 mM NaCl, 5 mM DTT.  TEV protease 
was added to the pooled sample in a 1:10 ratio of TEV to Keap1 and dialyzed overnight 
at room temperature.  The mixture was then run over a 1 mL HisTrap HP column and the 
column washed with 5 CV of 50 mM Tris pH 8.0, 500 mM NaCl and 5 mM DTT and the 
eluent containing the purified protein collected for visualization with gel electrophoresis 
(Figure 1.7).  The purified protein was dialyzed against a storage buffer containing 25 
mM Tris pH 8.0 and 10 mM DTT and concentrated to 5 mg/mL, flash frozen in liquid 
nitrogen and stored at -80 °C. 
1.2.3 Crystallization 
 Prior to initial crystallization, frozen protein was thawed on ice and the 
polydispersity checked by dynamic light scattering (Figure 1.8).  Protein with less than 
30% polydispersity was used for crystallization trials. The initial condition of 1.5M 
Ammonium Sulfate, 100 mM Bis Tris 6.5 and 0.1M sodium chloride was discovered 
using the Index screen from Hampton Research.  Grid screening around this condition 
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resulted in determination of the final condition: 1.2-1.3M ammonium Sulfate, 100 mM 
Bis Tris pH 6.0, 0.8% PEG 550 monomethyl ether (Figure 1.9).  Crystals from this 
condition were cryo-cooled in gaseous nitrogen for initial data collection. A peptide 
containing the sequence LDEETGEF was obtained from GenScript with an N-terminal 
acetylation and a C-terminal methylation for use in soaking experiments.  A 4mM stock 
of peptide was made in 25 mM Tris 8.0 and 10 mM DTT. Peptide and glycerol were 
added to the crystallization drop to a final concentration of 1.6 mM ETGE peptide and 
32% glycerol and allowed to equilibrate for 1 hour.  Crystals were cryo-cooled in liquid 
nitrogen without further cryo-protection.  Fragment soaking was performed by adding a 
20 mM fragment solution to the crystallization drop and incubating from 20 minutes to 
overnight. Crystals were harvested and transferred to a stabilizing solution containing the 
crystal condition plus 15% glycerol followed by transfer to a stabilizing solution 
containing the crystal condition plus 30% glycerol before being cryo-cooled in liquid 
nitrogen. Crystallization conditions are summarized in Table 1.3 
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Table 1.3: Crystallization Method 
Method Hanging Drop 
Plate type VDX 
Temperature (K) 286 
Protein concentration 5.1 mg/mL 
Buffer composition of protein 
solution 
25 mM Tris pH 8, 5mM DTT 
Composition of reservoir solution 100mM Bis Tris pH 6, 1.3M Ammonium 
Sulfate 
Volume and ratio of drop 2 uL 1:1 
Volume of reservoir 0.5 mL 
1.2.4 Fragment Screening 
 Thermofluor experiments were carried out using an Realplex EP Mastercycler RT 
PCR. 1 mL of 20 µM Keap1 with 1 µL of 5000x Sypro Orange dye was prepared and 10 
µL of this protein solution added to each well of a 96 Eppendorf white well plate.  1-10 
µL of ligand solution from either the CMLD compounds (1-4 mM) or the Zenobia 
fragment library (10 mM) were added to the solution and the total volume brought to 20 
µL.  The plate was then sealed with clear seal film to prevent evaporation. The plate was 
then inserted into the RT-PCR machine and heated at a rate of 1 °C per minute.  
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Fluorescence was measured at 520 nm and the temperature of melting defined as the 
midpoint of the peak of the change in fluorescence intensity over time.  Assay data is 
shown in Figure 1.12. 
 
1.2.5 Data Collection and Processing 
 Data for the unliganded structure was collected at Boston University Department 
of Chemistry on a Microstar Cu Kα rotating-anode X-ray generator (Bruker) and a 
Platinum 135 CCD detector at 100K. Data was reduced using SAINT (AXS B. S.) and 
scaled using AXS from the Proteum2 software suite (AXS B.P.) to a resolution of 2.45 Å 
with unit cell dimensions of a = 162.80 Å, b = 69.32 Å, and c = 78.30 Å, α = γ = 90°, β = 
118.11°, and space group C2. Data for the Keap1-ETGE structure was collected at the 
Stanford Synchrotron Radiation Lightsource (Menlo Park, California) on beamline 12-2 
using a Dectris Pilatus 6M detector at 100K.  Data was processed with XDS to a 
resolution of 3.5 Å. Data for fragment datasets was collected at the National Synchrotron 
Light Source (Brookhaven National Laboratory, Upton, NY) on beamline X-29 using a 
single wavelength and an ADSC Quantum 315r nine quadrant CCD detector to 
resolutions from 2.23 Å to 2.30 Å.  Data collection statistics are summarized in Table 1.5 
and refinement statistics in Table 1.6 
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Table 1.4: Data Collection Statistics 
Name KEAP1-P2C KEAP1-HPP KEAP1-P1A8 KEAP1 KEAP1-ETGE 
Unit cell 
dimensions 
161.465 68.52 
77.68 90 
114.77 90 
161.465 
68.52 77.68 
90 62.23 90 
161.639 69.033 
78.293 90 
117.76 90 
162.795 
69.316 
78.296 90 
118.108 90 
78.397 70.14 
146.14 90 90.5 
90 
Space group C 1 2 1 C 1 2 1 C 1 2 1 C 1 2 1 I 1 2 1 
X-ray source NSLS X29 APS NSLS X29 Bruker SSRL 
Wavelength 1.075 0.97918 1.075 1.54 0.9795 
Resolution 
range (Å) 
(highest 
resolution shell 
in parenthesis) 
51.85-2.23 
(2.31-2.23) 
51.38-2.55 
(2.64-2.55) 
42.22-25.09 
(2.599-2.509) 
71.79-2.40 
(2.487-2.401) 
33.42-3.5 (3.62-
3.5) 
Total/unique 
reflections 
73711/37484(
2091/1502) 
34329(1979)/
23715(1004) 
97203(9115)/26
191(2518) 
209175 
(15029)/ 
30181 (3007) 
40463 
(3992)/12583 
(1285) 
Completeness 99.86 (98.94) 96.02 (88.38) 99.51 (96.62) 99.77 (99.70) 96.00 (96.8) 
I/sigma 12.62 (2.85) 14.70 (7.04) 12.59 (1.75) 6.36 (1.96) 7.2 (3.1) 
R-meas 
0.0552 ( 
0.395) 0.08417 0.138 0.2076 
0.225 
R-merge 3.9 (27.9) 5.95 (10.96) 11.78 (79.64) 20.76 (114.8) 29.09 (49.7) 
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Table 1.5: Refinement Statistics 
Refinement 
Statistics KEAP1-P2C KEAP1-HPP KEAP1-P1A8 KEAP1 
KEAP1-
ETGE 
No. of protein 
atoms per ASU 4310 4401 4401 4304 4097 
Number of 
reflections 
work/free 35485/1999 22716/999 46367/3816 28095/2002 3023/341 
Rwork/Rfree 
0.1935 
(0.2310) / 
0.2472 
(0.2688) 
0.2075 
(0.2472) / 
0.2577 
(0.2868) 
0.2218 
(0.3609)/0.2753 
(0.4047) 
0.2477 
(0.2924) / 
0.3001 
(0.3330) 
29.53 
(35.86)/35.43 
(38.90) 
Average B-
factor 41.4 41.1 47.5 48.2 77 
Protein 41.3 41.3 47.5 48.5 76.8 
Water 40.7 33.5 
 
41.9 - 
Ligand P2C - 54.50 HPP - 54.10 P1A8 - 46.90 - 
ETGE - 
76.13 
RMS Bond 
lengths 0.011 0.013 0.01 0.01 0.005 
RMS angle 
lengths 1.21 2.24 1.39 1.4 1.3 
  
Molecular replacement was determined using Phaser (51) and PDB entry 1U6D  
selected due to sufficient resolution (1.8 Å) and the model used for phasing of a partially 
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open form of Keap1 (44)(28) followed by model building with Phenix.Autobuild and 
Coot (52). Residues that were visible and modeled in the electron density were the 
following: residues 322 to 609 in KEAP1, residues 325-609 in KEAP1-ETGE and 
KEAP1-P2C, 325-611 in KEAP1P1A8, 330-610 in KEAP1-HPP. 
 
1.3 Results and Discussion 
1.3.1 Purification and Crystallization of Keap1 
 The Keap1-ATA mutant was obtained from Stefan Jehle and transformed into the 
SoluBL21 expression cell strain successfully.  Keap1 expresses at a high level and was 
able to be purified with an average yield of 5 mg/L of culture with over 90% purity and 
less than 30% polydispersity as assessed by dynamic light scattering (see Figures 1.7, 
1.8). Initial crystals were found in the Hampton Research Index Screen and screened for 
X-ray diffraction on the Bruker Cu Kα rotating-anode X-ray generator (BU).  Crystals 
were screened for protein diffraction as well as for the presence of a unit cell and 
condition that differed from previously reported structures.  The condition that resulted in 
the new crystal form was optimized to the final condition of 100mM Bis Tris pH 6.0, 
1.2M Ammonium Sulfate, 0.8% PEG 550 MME (See Figure 1.9).  These crystals gave 
reproducible diffraction to 2.1-2.4 Å. 
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Figure 1.6: Purified Keap1 eluted after TEV cleavage.   
The band between 25 and 35 kDa on the protein ladder shows Keap1. The ladder is labeled in lane 1 and 
fractions 6-16,33-34 are listed in lanes 2-11.  Fractions such as 13-16, that appear over 90% pure were 
concentrated and used for crystallization. 
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Figure 1.7: Dynamic Light Scattering of Keap1. 
 Measurement of a Keap1 sample showing monodispersity suitable for crystallization experiments. The radius of 
the measured particles in solution are shown on the x-axis as R(nm) and the percentage of mass in the solution 
on the y-axis. 
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Figure 1.8: Keap1 Crystal  
50mM Bis Tris pH 6.0, 1.2M Ammonium Sulfate, 0.8% PEG 550 MME.  The size of this crystal (300 x 500 µm) 
is representative of the crystals seen in optimized conditions. 
1.3.2 Overall Structure 
 As shown earlier in Figure 1.1, the structure of KEAP1 makes up a β-propeller 
with 6 blades.  Each of the blades are labeled 1 through 6 in amino acid sequence order 
and the individual strands labeled A through D from inside to outside, following 
previously reported notation. (29) The propeller starts with strand B in blade 1 and is 
completed by the C-terminus forming a closure with strand A in blade 1. The active site 
is found towards the center of the protein, flanked by loops between strands B and C, 
which make up a binding pocket on one side of the protein. 
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1.3.3 Comparison with Previously Reported Structures 
 The overall structure of Keap1 is consistent with previously reported high 
resolution structures of Keap1.(29)  The crystal reported in this chapter is a novel crystal 
form of Keap1 with a more solvent-accessible active site and therefore differs in 
arrangement from other previously reported structures. The main difference being the 
number of copies of the molecule in the asymmetric unit.  In each asymmetric unit of the 
new crystal form, there is a one copy with a crystal contact in the active site, and one 
copy without a crystal contact.  The molecule without a crystal contact contains an active 
site that is accessible to the solvent and any ligands added to the crystal. This form is thus 
amenable for soaking experiments and for experiments to assess interactions at the active 
site since there intermolecular interactions will not be convoluted with active site 
interactions.  The new structures reported in this chapter each have two copies of the 
molecule in the asymmetric unit, similar to 3ZGD and 3ZGC but other structures such as 
1ZGK have only one. For continuity between structures, chain A has been defined as the 
molecule with a crystal contact in the active site, while chain B is the molecule with the 
accessible active site.  In the KEAP1 structure the root-mean-square deviation (RMSD) 
between chains A and B is 0.264 Å.(53) While the change in crystal packing makes it 
impossible to overlay the two molecules in the asymmetric unit of the KEAP1 structure 
with 3ZGD, the individual chains can be compared. The RMSD between chains A and B 
of KEAP1 to the 1.35 Å 1ZGK structure is 0.323 Å, and 0.309 Å respectively with the 
largest difference between structures being a small change in the orientation of loop 
residues 345-350.  The overall structure of Keap1 is also consistent with 3ZGD (44) with 
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a RMSD of 0.280 Å between chains A and A and 0.272 Å between chains B and B.   The 
similarity between the KEAP1 structure reported in this chapter and the published 
structures indicates that this construct and crystallization condition are suitable for 
investigation of binding at the active site of Keap1. 
1.3.4 Crystal Packing 
 The crystal packing of the reported structure is shifted so that the chain containing 
an accessible ligand binding site is more open than other previously reported structures. 
As shown in Figure 1.10, in 3ZGD chain A the 2 B-C loop sticks into the active site and 
chain B blade 2 B-C loop interacts with blade 6 B-C loop. In KEAP1 chain A blade 2 B-
C loop sticks into the active site and chain B blade 2 BC-loop interacts with the inter-
blade D-A loop between blades 1 and 2. This difference in interaction results in a shifting 
of chain B away from the active site and opening it to the solvent channel.  
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Figure 1.9: 3ZGD overlay (yellow) with KEAP1 structure (blue).   
The active site is shown in red spheres of van der Waals radius modeled from the linear ETGE peptide in the 
KEAP1-ETGE structure.   
 Also of note are the B-factors, a measure of relative vibrational motion and 
disorder. In the KEAP1 structurethe protein chain containing the more accessible active 
site has a higher B-factorwhich indicates that this chain is comparatively less well-
ordered than the chain with the crystal contact in the active site. The region with the 
highest B-factors is furthest from the active site, indicating that active site binding could 
promote a change in overall conformation to a more well-ordered protein structure within 
the crystal. This hypothesis is supported by data from the KEAP1-ETGE structure, as the 
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B-factors in the ETGE-bound chain more closely resemble the B-factors in the crystal 
contact-stabilized chain as seen in Figure 1.11. 
 
Figure 1.10: Ribbon diagram of KEAP1 (left) and KEAP1-ETGE (right) colored by B-factor from blue (low) to 
red (high). 
The location of the active is indicated by the arrow with the ETGE peptide shown in the model on the right. 
1.3.5 Peptide Complex Comparison 
 The interaction of the linear ETGE peptide (LDEETGEF) in KEAP1-ETGE is in 
agreement with other structures with the peptide ligand present (PDB ID 3ZGC, 4IFL). A 
comparison of 3ZGC and KEAP1-ETGE is displayed in Figure 1.12. In the 3ZGC 
structure of Keap1, the cyclized ETGE peptide Arg415 forms a salt bridge with Glu79, 
Arg380 forms a salt bridge with Glu82, Tyr572 forms a hydrogen bond through water to 
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Glu78, and Glu530 forms a hydrogen bond to Glu78.  The side-chain conformation of 
Glu79 is different from a previously reported structure co-crystallized with an ETGE 
peptide (PDB ID: 2FLU) as Asp77 and Glu78 deviate (RMSD of 1.5 Å) due to the cyclic 
peptide used in the soak. Glu78 is not well defined in the electron density of the linear 
peptide in 2FLU and for that reason is not included in this comparison.  In the 3ZGC, it 
appears that Gly76, the residue that links the peptide into a cycle may also be making a 
hydrogen bond interaction with Asn387 of the other chain in the asymmetric unit.  While 
the KEAP1-ETGE forms the same salt bridges with Glu-Arg, and the same hydrogen 
bonding network between Tyr-Glu-Glu, it lacks any additional interactions with the 
neighboring chain in the structure, making it an excellent example of the utility of this 
crystal form for soaking with larger ligands.  Binding of larger ligands in this open active 
site, without any additional binding interactions from crystal contacts, provides a better 
representation of the binding contributions at the active site of Keap1. 
 
Figure 1.11: Polar contacts between the cyclized (left) and linear (right) ETGE peptides (pink) and Keap1 in 
3ZGC (left, blue) and Keap1-ETGE structure (right, yellow). 
The polar contact between the ETGE peptide and the adjacent chain in 3ZGC is absent in the KEAP1-ETGE 
structure. 
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1.3.6 Fragment Screening of Keap1 
 To make the best use of this new crystal form of Keap1, the Zenobia fragment 
library and compounds provided by the Boston University Center for Chemical 
Methodology and Library Development (CMLD) were used in differential scanning 
fluorimetry experiments to identify fragment binding.  The Zenobia fragment library 
contains small molecule fragments optimized for central nervous system diseases, which 
would be beneficial in developing a therapeutic for Alzheimer’s disease.  Fragments were 
ranked by the increase in melting temperature observed as the protein was slowly heated, 
indicating stabilization of the Keap1 molecule and a possible binding interaction based on 
a previously published method(54). A summary of those fragments can be found in Table 
1.2. These fragments, combined with fragments identified by Mengqi Zhong in the 
Whitty lab at Boston University were used in soaking experiments to crystallographically 
validate a binding interaction for these fragments.  These soaking experiments resulted in 
three solved structures with fragments bound in the active site.  
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Figure 1.12: Differential Scanning Fluorimetry  
Data showing the temperature of melting (Tm) of Keap1 in the presence of small molecule fragments. The red 
line indicates the threshold of the peak used to determine the melting temperature and the green line is the point 
at which all wells are completely unfolded. 
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Table 1.6: Fragment hits from  Fragment Library and the CMLD. 
CMLD compounds were measured twice at concentrations of 1 mM and 4mM.  Zenobia compounds were 
measured once at a concentration of 10 mM 
Average 
Tm shift 
CMLD Compound  
Average 
Tm shift 
Zenobia Compound 
+2.5 (+/- 
0.6) 
 
 +4.8 
 
4-amino-6-
mercaptopyrazolo[3,4-
d]pyrimidine 
+2.6 (+/- 
0.8) 
 
 
 +4.6 
 
4-oxo-4H-1-benzopyran-2-
carboxylic acid 
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+2.3 (+/- 
0.7) 
 
 
 +4.2 
 
2-methyl-1,3-
cyclohexanedione 
+2.7 (+/- 
10.0)  
 
 +3.9 
 
5-chloro-2-
mercaptobenzoxazole 
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+2.6 (+/- 
0.3) 
 
 
 +3.8 
 
2,6-Pyridinedicarboxylic acid 
+2.3 (+/- 
0.9) 
 
 
 +3.1 
 
6-Methyl-2,3-
pyridinedicarboxylic acid 
+2.4 (+/- 
0.3) 
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+2.9 (+/- 
0.8) 
 
   
+2.6 (+/- 
0.2) 
 
   
+2.7 (+/- 
1.6) 
 
   
1.3.7 Identification of Binding Determinants 
 The validated fragments (shown in Table 1.5) 4-amino-6-mercaptopyrazolo[3,4-
d]pyrimidine (P1A8), 4-oxo-4H-1-benzopyran-2-carboxylic acid (P2C), and 3-(4-
Hydroxyphenyl)propionic acid (HPP) in these structures bind in close proximity to each 
other and make interactions with some overlapping residues in Keap1. This region was 
predicted to be the top-ranked binding pocket by collaborators in the Vajda Lab at Boston 
University using the program FTMAP (See Figure 1.13).(55) The three fragments found 
in the ligand structures share interactions with Arg483 and the backbone of Ser555 
(Figure 1.14).  The HPP and P2C fragments also make additional interactions with 
Arg415. P2C alone makes an interaction with Arg415.  
 
Table 1.7: Structurally identified fragment ligands of Keap1. 
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Structure 
 
 
 
Name 4-amino-6-
mercaptopyrazolo[3,4-
d]pyrimidine (P1A8) 
4-oxo-4H-1-
benzopyran-2-
carboxylic acid 
(P2C) 
3-(4-
Hydroxyphenyl)propionic 
acid (HPP) 
 
 Taking a closer look at the binding of these fragments in the Keap1 active site 
indicates the location of key binding determinants in this interaction. These arginine 
residues coordinate a key glutamate residue in the ETGE motif of Nrf2 and they adopt a 
similar interaction with the carboxyl group of P2C and HPP as seen in Figure 1.15.  The 
binding of the HPP fragment shows a slightly different orientation of Arg415 in the 
active site.  Alanine scanning mutation studies performed by Mengqi Zhong in the Whitty 
lab identified the role of each residue by measuring ETGE peptide/Keap1 binding. The 
decrease in binding affinity of those peptide variants are depicted in Figure 1.16.  It is 
reported that mutations in the Keap1 active site confirm the importance of these arginine 
residues (Figure 1.17).(20) This binding hot spot occupied by the glutamate residue in the 
ETGE peptide is also occupied by crystal contacts in structures reported in this chapter as 
well as previously published structures.(28, 44)  Aspartate or threonine residues within 
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these crystal contacts are found near the position of the key glutamate residue of the 
ETGE peptide but adopt a different orientation in the active site, as shown in Figure 1.18. 
The bicyclic ring structures overlap rings from the benzenesulfonyl-pyrimidone and N-
phenyl benzenesulfonamide type inhibitors discussed earlier in this chapter, indicating a 
possible pi-pi stacking interaction with a nearby tyrosine residue (See Figure 1.19). This 
tyrosine residue is a key component of the Keap1 active site binding, as mutation disrupts 
binding to Nrf2 as depicted in Figure 1.17. Together, these fragment structures validate 
the binding observed in initial assays and indicate potential binding interactions that 
could be of use in future inhibitor designs. 
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Figure 1.13: (top) Fragments P1A8, HPP, P2C found in the active site of KEAP1-P1A8, KEAP1-HPP and 
KEAP1-P2C structures (surface features calculated from KEAP1-HPP). (bottom) 
Computationally predicted fragment binding consensus sites from FTMAP.  The fragments solved in this 
chapter are located in the site occupied by the brown consensus models in this figure. 
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Figure 1.14: Models of ligand-bound Keap1. 
KEAP1-HPP (top), KEAP1-P1A8 (middle), KEAP1-P2C (bottom).  Interactions shown as dashes between HPP 
with Arg483, Ser508 and Ser555, P1A8 with Arg483 and Ser555, P2C10 with Arg415, Arg483, Ser508 and 
Ser555. 
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Figure 1.15: Overlay of ligands in the Keap1 active site. 
 This shows the overlap between the different ligands occupying the Keap1 active site.  This includes the 
carboxylate functional group of the P2C and HPP ligands with the carboxylate group of glutamate in the ETGE 
peptide, the conserved ring structures between P1A8 and P2C and overlapping carboxylate groups in crystal 
contact loops. 
 
Figure 1.16: ETGE binding mutations. 
Residues were mutated to alanine and binding to Keap1 measured. Alanine mutations that resulted in loss of 
binding are shown in pink, mutations that reduced binding affinity are shown in orange.  Mutations that had no 
effect are shown in green and residues not yet studied are indicated in blue. [Data provided by Mengqi Zhong in 
the Whitty Lab, BU] 
  
44 
 
Figure 1.17: Mutations in the Keap1 active site that disrupt binding to Nrf2.(20)  
Residues where mutation to alanine resulted in loss of Nrf2 binding shown in pink, residues with reduced 
binding affinity are shown in orange.. 
 
Figure 1.18: Overlay of crystal contact loops from 3ZGC (yellow) 1U6D (green) and KEAP1 (blue). 
In 3ZGC and KEAP1, a glutamate residue is occupying the same location as the glutamate residue from the 
ETGE motif and the P2C and HPP fragments.  In 1U6D this residue is a threonine. 
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Figure 1.19: Overlay of P1A8 and P2C fragments and Biogen 15 compound (left) and Biogen 16 (right).(56) 
The overlap between the ring structure of P2C, P1A8 and the bridging ring structures of the previously 
published symmetric ligands occupy a similar site. 
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Figure 1.20 Water analysis in the Keap1 active site. 
Conserved waters between PDB models are shown here in the active site.  Based on their location, two serine 
residues are identified as water-binding hot spots. 
1.4 Conclusions and Future Work 
 My work in this chapter has provided a method of validation for small molecule 
fragment binding to the binding site of Keap1, reported the discovery of a novel crystal 
packing form of Keap1 that allows structural determination of larger ligands in complex 
with Keap1 and identification and classification of hot spot regions in the Keap1 binding 
site.  Overall, four structures of Keap1 demonstrate the utility of the reported 
crystallization method for validating noncovalent inhibitors of the Keap1-Nrf2 
interaction.  The KEAP1-ETGE structure shows the accessibility of the Keap1 binding 
site for soaking with larger ligands. This accessibility could facilitate future studies with 
  
47 
peptides corresponding to different Keap1 binding motifs or mutations to verify the 
structural basis for key residues in the motif.  The Keap1 fragment structures confirm six 
hot spot regions and identify overlapping functional groups that can be used as a basis for 
future inhibitor design. Additional compounds with similarity to fragment P2C were 
produced by the CMLD and have been screened alongside top-ranked fragment hits from 
the Zenobia library.  Future structural validation of these compounds could indicate a 
direction of fragment growth or linkage and an important step in fragment-based drug 
design strategies. 
 
  
48 
CHAPTER TWO 
2.1 NEMO/IKKβ Introduction and Literature Review 
2.1.1 NF-κB Signaling Pathway 
 Transcriptional regulation is an important mechanism that allows cells to respond 
to a number of different stimuli. Transcription factors are proteins or protein complexes 
that function as key activators or repressors of transcriptional regulation.  One such 
transcription factor is kappa-light-chain-enhancer of activated B cells (NF-κB) which 
gives the cell the ability to respond to extracellular stress, as well as regulate cell 
differentiation and proliferation (57).  NF-κB is a heterodimer consisting of proteins from 
the Rel family which share a Rel homology region (RHR). (58)  In most cells, NF-κB 
remains in its inactive form and must become activated before it can regulate 
transcription. (59)  NF-κB is inactivated by sequestration in the cytosol by four proteins: 
IκBα, IκBβ, IκBε, and IκBγ (IκBs). (57)  Activation of NF-κB occurs primarily through 
the degradation of the IκBs by the proteasome-mediated, triggered by phosphorylation of 
IκB by the IκB kinase (IKK). (57, 59) IKK contains three components: IKKα, IKKβ and 
NF-κB essential modulator (NEMO) (60, 61). As indicated in Figure 2.1, disruption of 
the IKK complex would result in NF-κB repression.  
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Figure 2.1: NF-κB activation pathway. 
The IKK complex (1) formed by association (B2) of NEMO and IKKβ phosphorylates (B3) IκB leading to its 
degradation (B4).  This leaves NF-κB, shown as RelA and p50 able to translocate to the nucleus and upregulate a 
gene response. If that association is disrupted (A2), the complex is unable to phosphorylate IκB and prevents the 
NF-κB pathway from being upregulated. 
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2.1.2 NF-κB and Disease 
 The role of the NF-κB signaling pathway in disease has been well studied in terms 
of its role in inflammation (62, 63), cancer (64) and immunodeficiency. (65) Knockout of 
NEMO in a mouse model causes fatal liver damage stemming from uncontrolled 
apoptosis due to a lack of NF-κB mediated survival signaling in hepatocytes. (66) 
Knockout of IKKβ in the same mouse model has a similar result with the main difference 
being a delay in the onset of liver degeneration. (67)   NF-κB has been shown to 
play a role in cell proliferation and differentiation and these pathways can become 
upregulated in certain types of cancer. (68–71) Its role in immune regulation has been 
demonstrated in diseases where human genetic defects in NEMO give rise to pathologies 
such as incontinentia pigmenti and cylindromatosis. (65) The role of the NF-κB pathway 
in disease has led to its study as a possible therapeutic target (72, 73). 
 Studies of the NEMO/IKK interaction have shown that the IKK complex can be 
disrupted with a peptide called the NEMO binding domain (NBD).  NBD peptides were 
used in a cell system to show that disruption of the NEMO/IKK interaction inhibit 
inflammation-induced cytokine production without disruption of basal cytokine 
production.(73)  The activity of the NBD peptide in this study indicates that a 
NEMO/IKKβ disruptor would be a good drug target, as the response to inflammation can 
be modified without interfering with processes critical to the cell.   
2.1.3 Pathways of NF-κB Activation 
 Two pathways of activation for NF-κB are distinguished as canonical and 
noncanonical.  The noncanonical pathway of activation does not involve NEMO and is 
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linked to organism development, while the canonical pathway of activation uses NEMO 
and is linked to immune response (74).  In the IKK complex canonical activation 
pathway, there are three mechanisms that all involve multi-protein complex formation.  
The first requires an E2/E3 ligase complex consisting of UbcH5 and cIAP1 recruitment 
to the TNF-receptor 1.  The complex then causes polyubiquitination of the kinase RIP1.  
The IKK complex along with TAK1 kinase binds to the ubiquitin chains and IKK 
becomes phosphorylated by TAK1 and through trans-autophosphorylation (75–77).  In 
the second mechanism, the ubiquitin ligase complex LUBAC associates with the TNF 
receptor 1, causes polyubiquitination of NEMO and the IKK complex becomes activated 
by trans-autophosphorylation (78, 79).  In the third mechanism the E2/E3 ubiquitin ligase 
complex of Ubc13 and TRAF6 conjugates K63 ubiquitin chains to IRAK1, recruiting the 
IKK complex and TAK1 and follows the same phosphorylation activation method as 
mechanism 1. (76, 80) 
 Once the IKK complex has been activated, IκB becomes phosphorylated by IKK 
and then ubiquitinated by the E3 ubiquitin ligase SCF/ΒTRCP and degraded by the 26s 
proteasome. (78, 81, 82) The NF-κB transcription factors that were bound to IκB are thus 
freed to translocate to the nucleus and upregulate the target genes.  As the IKK complex 
is the primary activator for NF-κB in this mechanism, disruption of this complex 
formation by blocking the NEMO/IKKβ interaction would effectively inhibit this 
pathway.  The binding of IKKβ to NEMO has been well-studied and the minimal IKKβ 
11mer that binds and inhibits NEMO identified (residues 734-744).(83)  Use of a cell-
penetrating variant of the IKKβ peptide shows that disruption of the NEMO/IKKβ 
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interaction can inhibit activation of NF-κB but does not affect basal NF-κB function, 
which adds to the attractiveness of this interaction as a therapeutic target  (73).   
2.1.4 NEMO/IKKβ Structure and Function 
 The NEMO/IKKβ interaction is a crucial part of the NF- κB signaling pathway. 
The IKK complex forms in a 2:2 ratio with two molecules each of NEMO binding two 
molecules of IKKβ.  (72)  Other ratios have also been proposed for complex formation. 
(60, 84–86)  Many different oligomerization states have been proposed for NEMO from 
monomer to pentamers (60, 72, 84–94) but the three-dimensional structures of domains 
of NEMO that have been published indicate a dimeric structure in an extended rod-like 
shape, consistent with AUC data (89).  While the full-length structure has not yet been 
solved, there are several unique domain structures available, though none of these 
fragment structures includes the 44 residues at the N-terminus or the section from residue 
111 to 196. (72, 90–95)  These characterized regions, depicted in Figure 2.2, show the 
regions of NEMO including the HLX1/CC1/IKKβ binding region (44-111), the 
intervening region (111-195), the HLX2 region (196-249), the coiled-coil 2  (CL2) region 
(251-285), the leucine zipper (LZ) (301-337), and the zinc finger (387-419).  With the 
exception of the C-terminal zinc finger, the structures show a highly helical coiled coil 
structure. (95) 
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Figure 2.2: NEMO Structure.   
NEMO dimer is shown in tan with bound IKKβ in red and di-ubiquitin in gold.  Unmodeled regions of the 
dimer are shown as red dots. Figure courtesy of Adrian Whitty. 
 The previously published structures of domains of NEMO are summarized in 
Table 2.1.  With the exception of 2JVX and 2JVY, which have been determined by 
NMR, all reported structures have been determined by X-ray crystallography.  Two 
structures of a fragment containing residues 44 to 111 have been reported with PDB IDs 
3BRV and 3BRT. The 3BRV structure was solved with an IKKβ fragment containing 
residues 701-746 and the 3BRT structure was solved with a fusion protein containing 
residues 701-730 from IKKβ and residues 731-745 from IKKα.  There is a single 
structure of the HLX2 region of NEMO with PDB ID 3CL3.  This region is co-
crystallized with a viral Fas-associated death domain interleukin -1β-converting enzyme 
inhibitory protein (vFLIP), produced by Kaposi’s sarcoma herpes virus that associates 
with this region to activate the NF-κB transcription process. The CL2 and LZ regions of 
NEMO, sometimes referred to collectively as CoZi region, have a number of associated 
structures.  The structure of the CoZi region of NEMO is crystallized with diubiquitin 
(2VZN), a designed ankyrin repeat protein (DARPin, 2V4H) or alone and shows residues 
253 to 337.  The C-terminal Zinc finger region of NEMO has been characterized by 
NMR with ensemble solution structure 2JVX containing residues 394-419. 
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Table 2.1: Previously reported structures of NEMO fragments 
PDB 
ID 
NEMO 
construct Ligand Mutations Organism Solution Method 
3BRV 44-111 IKKβ 701-746 - Human 
X-ray 
Crystallography 
3BRT 44-111 
IKK fusion 
protein - Human 
X-ray 
Crystallography 
3CL3 192-252 vFLIP 2-173 - Human 
X-ray 
Crystallography 
3FX0 246-337 - - Human 
X-ray 
Crystallography 
2ZVN 253-337 diubiquitin - Human 
X-ray 
Crystallography 
3F89 254-336 - K285N Mouse 
X-ray 
Crystallography 
2ZVO 250-337 diubiquitin 
E282A, 
K285A Mouse 
X-ray 
Crystallography 
4OWF 251-336 
ubiquitin 
ligase - Mouse 
X-ray 
Crystallography 
3JSV 249-343 diubiquitin - Mouse 
X-ray 
Crystallography 
  
55 
2V4H 251-337 Darpin - Mouse 
X-ray 
Crystallography 
2JVX 394-419 - - Human NMR 
2JVY 394-419 - C417F Human NMR 
  
Some structural data of the NEMO/IKKβ interaction site has been previously 
reported.  The structure of the IKKβ binding region of NEMO in complex with a 44mer 
IKKβ peptide (residues 701-745) illustrates the binding groove, leading to assessments of 
druggability.(96) Alanine scanning mutagenesis identifies residues that contribute a large 
portion of the binding interaction (97).  This mutagenesis study showed that a small 
number of residues contribute a large portion of the binding interaction energy(83, 97). 
The three groups of residues making the highest contributions to binding affinity are 
residues L708, L719 and D738-L742.  These residues likely indicate hot spots in the 
protein-protein interface that could be blocked by inhibitors or fragments in future 
studies.  Mutational studies of cysteine residues in full-length NEMO protein have also 
identified a construct bearing mutations C11A, C54A, C76A, C95A, C131A, C167A, and 
C347A that produces a highly soluble homogeneous dimer that binds IKKβ (98).  This 
construct can pave the way for additional structural study of the protein-protein interface 
and create a platform for confirmation of the hot spots indicated by the previously 
reported mutational study through fragment and ligand-binding studies. 
 Additional small angle X-ray scattering (SAXS) and binding data with a 44-195 
construct of NEMO (data from Rob Shaffer and Stefan Jehle) indicate that the 111-195 
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intervening region domain of NEMO plays a role in IKKβ binding.  SAXS is a method 
that allows for reconstruction of a molecule in solution at low resolution.  In SAXS parts 
of the model that are well-ordered show up as a region of high scattering intensity, 
whereas unstructured or highly mobile regions of a molecule are not visible.  In the 
SAXS model of full-length NEMO, for example, the intervening region of NEMO 
(shown in Figure 2.3) is present within a low-resolution envelope of the structure.  This 
differs from the more mobile zinc finger domain, which may be unstructured due to the 
lack of zinc in the buffer and the N- termini of NEMO, which is expected to be 
disordered. (72). Binding studies by Rob Shaffer (unpublished) comparing constructs 
containing the IVR (residues 44 to 195) or just the N-terminal IKKβ binding domain (1 to 
120) shows that the IVR containing construct binds to IKKβ 10 fold more tightly than the 
N-terminal IKKβ binding domain alone.  In addition, the intervening region is well 
conserved among iso-functional orthologs of NEMO. This data supports the hypothesis 
that the intervening region of NEMO is structured and plays a role in the protein-protein 
interaction between NEMO and IKKβ. 
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Figure 2.3: Small Angle X-Ray Scattering model of full length NEMO.   
A model of a 1-419 residue NEMO dimer represented by spheres is fit inside the molecular envelope generated 
from SAXS data obtained using a full-length NEMO construct.  The intervening region is shown inside the red 
box. Disordered regions are indicated with blue arrows. [Jehle, Shaffer et al., unpublished] 
 Disruption of the protein-protein interaction between NEMO and IKKβ would 
prevent the IKK complex from activating the NF-κB pathway. This disruption could be a 
therapeutic point of intervention in diseases where NF-κB hyperactivity is linked to 
cancer or inflammatory disease. To better understand the binding interactions between 
NEMO and IKKβ we report in this chapter the crystallization of various constructs of 
NEMO cocrystallized with IKKβ. 
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2.2 Materials and Methods 
2.2.1 NEMO Constructs 
 NEMO constructs were provided by Li Zhou, Carmine Ballarano and Rob Shaffer 
of the Whitty group.  Constructs provided contained residues 1-120, 44-111, 44-195 and 
full length NEMO.  All constructs had the following mutations: C11A, C76A, and C95A. 
The full length construct (7XALA ) contained C54A, 131A, C167A, C347A as well.  The 
44-195 construct had C131A and C167A mutations. The 1-120 construct was also 
supplied with a L107C mutation. An IKKβ fragment (701-745) was provided in mutant 
form (Cys to Ala) for co-crystallization with 1-120.  The 11mer and a 45mer peptide 
derived from IKKβ were provided by the Whitty Lab.  Protein was supplied at a 
concentration of 300 µM, which was estimated by gel electrophoresis.  Ligands for co-
crystallization (7834, 8086 and 7801) were provided by Carmot.  The constructs, their 
identifiers and mutations are listed in Table 2.2.  
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Table 2.2: List of NEMO/IKKβ Constructs. 
Construct 
Identifier 
1-120 1-120M1 44-111 44-195 7XALA IKKβM1 IKKβ11M2 IKKβ45 
Residues 1-120 1-120 44-111 44-195 1-419 704-745 735-744 704-745 
Mutations 
 
C11A, 
C76A, 
C95A 
C11A, 
C76A, 
C95A, 
L107C 
C76A 
C76A, 
C131A, 
C167A 
C11A, 
C54A, 
C76A, 
C95A, 
C131A, 
C167A 
C347A  
C716S 
FITC 
labeled 
None C716S 
2.2.2 Crystallization 
 Initial crystallization trials were performed using the vapor diffusion method with 
sitting drop geometry at 17 °C with the high throughput screens: Index, PEG/Ion, PegRx, 
SaltRx (Hampton Research) and MCSG (Microlytic) in Corning 3552 96 Well Plates 
with 50 µL of well solution and 2 µL drops in a 1:1 ratio protein:precipitant. Grid 
screening and optimization was performed via hanging drop vapor diffusion in Linbro 24 
well plates using 500 µL well solution and 2 µL drops in a 1:1 ratio of 
protein:precipitant.  A grid screen was performed based on the crystallization conditions 
published in the Rushe paper, while additional optimization screens were performed 
using hits from the high-throughput crystallization screening.(72)  Conditions were 
considered hits when they resulted in the formation of crystalline material and validated 
by measuring diffraction on an X-ray source.  The initial condition found was D8 from 
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the Index Screen (Hampton Research): 0.1 M HEPES 7.5, 25 % w/v Polyethylene glycol 
3350.  Final crystal formation conditions were in the range of 17.5 %-25 % PEG 3350 
and 0.1M HEPES 7.5.  Crystals derived from this condition were thin plates measuring 
100-200 μm on the longest axis and 10-30 μm on the shortest axis.  Small crystals were 
also observed when NEMO 44-195 was co-crystallized with Carmot Compound 7834 in 
condition F1 of the MCSG suite plate 1: 0.1M Bis-Tris:HCl pH 6.5, 20% (w/v) PEG 
MME5000. 
2.2.3 Data Collection 
 Data sets (summarized in Table 2.3) were collected at the Stanford Synchrotron 
Radiation Lightsource (Menlo Park, California) on beamlines 7-1 (NHG128) and 12-2 
(365C8, NHG04, NSM102) using a Dectris Pilatus 6M detector at 100K and at the 
Boston University Department of Chemistry on a Bruker Microstar Cu-kα rotating anode 
inboX-ray generator with a Platinum 135 CCD detector at 100K (50717, 50815, 50915).  
For soaking crystals for phase determination, 1-10 mM solutions (Hg, Sm, I) were added 
directly to the drop containing the crystals and allowed to equilibrate from 1 hour to 
overnight.  Crystals were cryo-protected with 30% glycerol and 40% glucose prior to 
flash-cooling in liquid nitrogen (for data collection at SSRL) and gaseous nitrogen at a 
temperature of 100 K (for data collection at the home source).   Data were processed with 
Proteum2 software suite, XDS and iMosflm. Resolution limits and statistics for these data 
sets are listed below in Table 2.3. 
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Table 2.3: Data Statistics of 44-195 and IKKβ11M2 
Dataset 
Identifier 
365C8 NHG04 NSM102 NHG128 50715 50815 50915 
Unit Cell 
41.677 Å 
41.213 Å 
59.239 Å 
90° 
98.453° 
90° 
41.97 Å 
39.62 Å 
58.22 Å 
90° 
97.8° 
90° 
41.78 Å 
40.37 Å 
58.05 Å 
90° 98.5° 
90° 
41.66 Å 
40.28 Å 
58.01 Å 
90° 98.2° 
90° 
57.98 Å 
36.08 Å 
81.16 Å 
90° 
100.36°  
90° 
58.068 Å 
36.142 Å 
81.234 Å 
90° 
100.452° 
90° 
58.068 Å 
36.142 Å 
81.234 Å 
90° 
100.452° 
90° 
Space Group P1211 P 1 21 1 P 1 21 1 P 1 21 1 P1 P1 21 1 P1 21 1 
Light Source SSRL SSRL SSRL SSRL BU BU BU 
Wavelength 0.9795 0.9698 0.9698 0.9698 1.54 1.54 1.54 
Resolution of 
Data (Highest 
Resolution 
Shell) (Å) 
33.71 - 
2.25 
(2.33-
2.25) 
57.68 - 
2.44 
(2.52-
2.44) 
57.48 - 
2.25 
(2.33 - 
2.25) 
32.97 - 
2.35 
(2.43 - 
2.35) 
57.03-
3.00 
57.10-
2.00 
57.10-
2.80 
Total/Unique 
Reflections 
15448 
(1480) / 
8394 
(831) 
13859 
(1397) / 
6963 
(704) 
17588 
(1721) / 
8861 
(869) 
6222 
(636) / 
4308 
(472) 
30323 
(2828) / 
12269 
(1187) 
67373 
(3724) / 
21175 
(1817) 
114620 
(1429) / 
8101 
(558) 
Completeness 
(%) 
87.2 
(87.8) 
95.8 
(97.4) 
95.4 
(94.8) 
53.1 
(58.6) 
94.7 
(94.1) 
92.0 
(80.1) 
95.8 
(67.4) 
I/σ 9.0 (2.0) 6.5 (2.8) 7.6 (2.6) 6.6 (2.2) 3.2 (1.8) 4.4 (2.9) 4.2 (1.9) 
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R-meas 
0.086 
(0.625) 
0.102 
(0.414) 
0.076 
(0.424) 
0.070 
(0.396) 
0.354 
(0.673) 
0.266 
(0.347) 
0.789 
(0.748) 
R-merge 
0.061 
(0.442) 
0.072 
(0.293) 
0.054 
(0.3) 
0.050 
(0.280) 
0.279 
(0.530) 
0.222 
(0.265) 
0.758 
(0.635) 
Dataset Type Native Hg Soak Sm Soak Hg Soak 
Magic 
Triangle 
Soak 
Magic 
Triangle 
Soak 
Magic 
Triangle 
Soak 
 
2.2.4 Molecular Replacement 
 The unit cell of the previously reported structure 3BRV is = 44.82 Å b = 50.67 Å 
c = 102.79 Å α = β = γ = 90°, whereas the unit cell found for initial data sets of 44-195 
with IKKβ11M2 is a = 40.48 Å b = 35.26 Å c = 57.57 Å α = γ = 90° β = 98°. 
Isomorphous replacement is not an option with this degree of difference between unit 
cells so molecular replacement is necessary to obtain phase information. The unit cell 
from the datasets 50715, 50815 and 050915 instead indexed as a = 58.3 Å b = 81.6 Å c = 
81.6 Å α = γ = 90 β = 100.90.  To find a molecular replacement solution, a number of 
different search models were prepared as indicated in Table 2.4. To begin with, simple 
models based on the previously solved portions of NEMO were utilized, but as those 
proved insufficient, more complex methods were used to generate additional search 
models.  The strategy for creation of these search models is discussed in the Results and 
Discussion section of this chapter.  3BRV was used as the basis for a number of 
molecular replacement models, but when that proved insufficient, Phyre2 was used to 
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generate a consensus model of 44-195 (99).  Molecular replacement was attempted with 
the Phyre2 model including the use of a model superimposed on the 3BRV structure to 
create a dimer.  A complete list of molecular replacement models can be found in Table 
2.4.  In addition to Phaser, the AMPLE program in the CCP4 suite was used to generate 
and test search models of NEMO. (100) Using AMPLE, protein fragments and decoys 
generated by Quark and Robetta, ab initio models of NEMO were built and used as 
search models for molecular replacement with MRBUMP.(100–102) The best molecular 
replacement solution from this process was used by BUCCANEER and Phenix 
AutoBuild to construct an initial model.   
Table 2.4: Molecular Replacement Search Models 
MR Model  NEMO 
modification 
IKKβ modification Model Source 
3BRV 44-111 dimer 44mer - 
3BRV  44-111 dimer IKKβ dimer shortened 
to 11mer 
Phenix PDBtool 
3BRV 44-111 dimer, 
mutated to 
poly-Ala 
IKKβ dimer shortened 
to 11mers, mutation ot 
poly-Ala 
Phenix PDBtool 
3BRV 44-111 
monomer 
 IKKβ 11mer 
monomer 
Phenix PDBtool 
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 44-111 
monomer, 
mutated to 
poly-Ala 
IKKβ 11mer 
monomer, mutated to 
poly-Ala 
Phenix PDBtool 
3BRV 44-111 dimer Removed Phenix PDBtool 
3BRV 44-111 dimer, 
polyAla 
Removed Phenix PDBtool 
3BRV  44-111 
monomer 
Removed Phenix PDBtool 
3BRV  44-111 
monomer, poly 
Ala 
Removed Phenix PDBtool 
Phyre2  44-195 
monomer 
- Phyre2 
Phyre2  44-195 
monomer, 
polyAla 
- Phyre2 
Phyre2  44-195 dimer Superimposed with 
3BRV to form dimer 
Phyre2, Coot 
Phyre2  44-195 dimer, 
polyAla 
Superimposed with 
3BRV to form dimer 
Phyre2, Coot 
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2EFR 13% sequence 
identity 
- PDB 
2OJA 13% sequence 
identity 
- PDB 
2D3E 12% sequence 
identity 
- PDB 
4A7F 13% sequence 
identity 
- PDB 
3O0Z 15% sequence 
identity 
- PDB 
2B9C 17% sequence 
identity 
- PDB 
2FXM 17% sequence 
identity 
- PDB 
1C1Q 10% sequence 
identity 
- PDB 
3Q8T 20% sequence 
identity 
- PDB 
3U59 15% sequence 
identity 
- PDB 
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4QKW 11% sequence 
identity 
- PDB 
4ILO 6% sequence 
identity 
- PDB 
4A55 9% sequence 
identity 
- PDB 
4I1B 10% sequence 
identity 
- PDB 
3Ol1 16% sequence 
identity 
- PDB 
3NA7 15% sequence 
identity 
- PDB 
3SWK 14% sequence 
identity 
- PDB 
3DTP 17% sequence 
identity 
- PDB 
1BF5 9% sequence 
identity 
- PDB 
2OCY 9% sequence 
identity 
- PDB 
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PDB ensemble Ensemble of 20 
PDB proteins 
 Ensembler 
(Phenix) 
 
2.2.5 Experimental Phase Determination 
 To solve the phase problem, heavy-atom incorporation into NEMO crystals was 
attempted via crystal soaking.  Heavy-atom soaking was attempted with C2H5HgO4P, 
K2PtCl4, SMCl3 and EuCl3 at a concentration of 1-10 mM. Crystals were prepared and 
datasets collected at SSRL as described above. Soaks with 10 mM 5-amino-2,4,6-
triiodobenzene-1,3-dicarboxylic acid were also performed using the Magic Triangle kit 
(Jena Biosciences).  Selenomethionine-substituted NEMO protein was supplied by Rob 
Shaffer and set up under the previously described optimized condition.  
2.3 Results and Discussion 
2.3.1 Crystallization of NEMO 
 Initial crystallization experiments with the 1-120 and 44-111 constructs of NEMO 
were unsuccessful in producing protein crystals and the high number of conditions 
resulting in phase separation (Figure 2.4) indicates the possibility that the NEMO 
construct was disordered in the absence of an IKKβ binding partner.  The 1-120 and 44-
111 constructs were rescreened under the initial conditions in the presence of equimolar 
IKKβ11M2  (see Table 2.2) and the rate of phase separation decreased.  This allowed for 
finer screening around the remaining phase separation conditions and other possible hits.  
Initial conditions were screened with approximately 300 µM 44-195 and equimolar 11-
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mer of IKKβ. These screens yielded the initial crystal hits shown in Figure 2.5. The 
conditions were optimized to the final conditions of 17.5 %-25 % PEG 3350 and 0.1M 
HEPES 7.5 and resulted in crystals similar to those shown in Figure 2.6 when grown for 
30 days at 17 °C. Co-crystallization of 44-195 construct with a compound provided by 
Carmot Therapeutics, compound 7834, a possible inhibitor, also showed crystal growth 
as seen in Figure 2.7.   These initial crystals with Carmot compound 7834 compound did 
not diffract but are promising for future optimization.  No construct of NEMO formed 
crystalline material in the absence of IKKβ, which may indicate that the presence of a 
binding partner stabilizes NEMO in a conformation suitable for crystallization.  Since 
Carmot 7834 stabilizes NEMO in the same manner, it may be an indication of binding.  
 
Figure 2.4: Phase separation observed in >70% of conditions of NEMO constructs containing residues 1 to 120. 
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Figure 2.5: Amorphous material found with initial screening of the NEMO construct containing residues 44 to 
195.  
This material was screened but no X-ray diffraction was observed. 
 
Figure 2.6: Crystal formation of the NEMO 44-195 construct after incubation with a 11mer peptide of IKKβ 
(residues 735-744).   
Crystals of this type reproducibly diffract to 2-3 Å 
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Figure 2.7; Crystalline precipitant that formed of NEMO construct 44-195 with Carmot compound 7834. 
2.3.2 NEMO dataset statistics 
 With the exception of the datasets collected at the home source, calculation of the 
Matthew’s coefficient indicates that, given the volume of the cell and the molecular 
weight of the NEMO construct, one copy of the 44-195 NEMO construct would give a 
unit cell with ~60% solvent content. This is consistent with the range of solvent content 
observed for protein.  The datasets collected at the home source have a larger unit cell 
where one unit cell axis is doubled and two copies of the NEMO construct are predicted 
in the asymmetric unit.  This increase in the size of the unit cell is typical in conditions 
where ligand binding induces a small conformational change that results in the loss of 
symmetry. (103) 
  
71 
2.3.4 Molecular Replacement 
 Molecular replacement was attempted to calculate phases for the each data set 
with Phaser.  Based on the size of the unit cell, one copy of 44-195 was predicted to 
occupy the unit cell in datasets 365C8, NHG04, NSM102, and NHG128.  Datasets 
50715, 50815, and 50915 were predicted to have two copies in the unit cell and the 
number of search model copies sought was adjusted accordingly. The 3BRV model of 
NEMO was used as the initial search model as it contains 44% of the residues from 44-
195 NEMO, as well as a 44mer of IKKβ with a dimer of NEMO and a dimer of IKKβ 
forming a four coil bundle. Variations on this search model included truncation of the 
IKKβ dimer to a 11mer, removal of IKKβ dimer, separation of the model into a 2 helix 
NEMO/IKKβ bundle, and mutation of residues within the models to a poly-alanine 
sequence.  Results from these molecular replacement attempts would result in many 
possible solutions, as the predicted helical structure of 44-195 could occupy many similar 
positions and orientations in the protein crystal while still fitting within helical density.  
 When modification of the 3BRV model proved insufficient for phase 
determination, it was thought that a more complete model of the 44-195 construct could 
result in a less ambiguous fit into the electron density.  Phyre2 was used to generate a 
consensus model of NEMO containing residues 44 to 195. (99) This process uses 
sequence alignment and secondary structure predictions along with homologous 
structures in the PDB to generate a full-length model of the protein of interest. The model 
created from this method represents 90-100% of the residues in the 44-195 construct and 
potentially results in a better search model if the predictions are correct.  Although the 
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number of ambiguously placed, poor molecular replacement solutions decreased 
compared to the attempts with the 3BRV-based models, in many cases no molecular 
replacement solution could be identified at all.  There is no structural information for 
residues 112 to 195 of NEMO, so the Phyre2 model relies on sequence and structural 
similarity to other reported structures to model this region.  Phyre2 models only a single 
monomer of the protein of interest and so does not take into account the dimeric structure 
of the NEMO coiled coil that is being modeled, which is a limitation of the software.  
Within these models the helices that overlap with NEMO have varied degrees of 
curvature, and differing orientation and tertiary structure.  This variance is an indication 
of the limitations of consensus modeling without structural information.  It is likely that 
the consensus structure of this region of NEMO differs from the 44-195 construct in the 
protein crystal in a way that does not allow for molecular replacement.  Each of the 
models identified by Phyre2 was used as a molecular replacement search model in the 
hopes of finding a model that shared similar helical curvature properties with 44-195 but 
these attempts resulted in the same challenges that occurred for the previously attempted 
3BRV and Phyre2 models.   
 An alternative molecular replacement method was investigated using the AMPLE 
program as part of the CCP4 suite of crystallographic software (100).  This program uses 
a combination of small poly-Alanine helices and ab initio protein construction to generate 
a large list of search models which are then used for molecular replacement.  Use of this 
method resulted in the most promising model of 44-195 built to date but this model has 
several deficiencies. 
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 The first issue is found in the region of the model built into the density of this 
dataset.  In the unit cell of this model there is enough room to build in one copy of the 44-
195 residue region of NEMO, but two copies of the same 50-120 residue region have 
been built instead.  This could indicate an error with the original indexing of the dataset 
where, due to translational pseudo-symmetry, a large unit cell has been erroneously 
indexed as being only half as large.  This superposition of two similar, but not identical 
halves of the unit cell would lead to construction of a model that would be an average of 
two similar but distinct regions.  The constructs of NEMO provided for crystallization are 
constitutive dimers and remain in that form throughout purification which is inconsistent 
with the calculated monomeric asymmetric unit. 
 The second issue with this model is the ambiguous placement of the side chain 
density in this model.  One of the methods of determining the quality of the phases in the 
crystallographic model is to investigate the presence of large side chains in the electron 
density, usually tryptophan or phenylalanine.  If those large side chains are removed 
before a round of refinement, density from data supporting the presence of that side chain 
should persist.  If the density disappears, however, it could be a sign of model bias, which 
is overfitting the available data, or of a poor phasing solution. Two phenylalanine 
residues were built onto two NEMO chains corresponding to residues 50 to 120 in the 
model depicted in Figure 2.8. Based on the number of molecules predicted in the 
asymmetric unit of the crystal, it was expected that two of those phenylalanine residues 
were built in error.  To determine which of the phenylalanines were placed incorrectly 
each phenylaline was mutated to alanine one at a time and refined. As depicted in Figure 
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2.8, the density does not persist after a round of refinement when the corresponding 
residues are changed to alanine.  This indicates that the density in that region is resulting 
from a poor phase solution and that the data does not support placement of a 
phenylalanine residue in that location.  Unfortunately, the density does not 
unambiguously indicate proper residue location.  
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Figure 2.8: Side chain ambiguity in a refined model of 44-195 NEMO. 
A,B: Chain A Phe38; C,D: Chain A Phe48; E, F: Chain B Phe38, G, H: Chain B Phe48.  Before (A,C,E,G) and 
after (B,D,F,H) refinement of four removed phenylalanine residues (pink) in the refined model of NEMO (tan). 
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 These deficiencies are difficult to address with computational methods, as the 
trial-and-error method of building these models results in a process that can take several 
weeks until a suitable model is built with no guarantee of success.  The molecular 
replacement challenges inherent in fitting a helical model make experimental phasing of 
this structure a more attractive option. 
2.3.5 Experimental Phasing of NEMO 
 In order to obtain the phases of the NEMO 44-195 construct dataset, heavy atom 
soaking and co-crystallization was attempted as described in the experimental section. 
When heavy atoms are present in the protein crystal, the diffraction observed will change 
due to absorption and emission by the heavy atoms.  This results in pairs of measured 
reflections that would normally have the same measured intensity diverging as the heavy 
atoms absorb and re-emit (scattering anomalously).  For datasets collected from heavy 
atom-soaked crystals, anomalous signal measured by the fraction of reflections with 
Bijoet related intensity differences was below 5% and insufficient to place heavy atoms 
in the density. Soaking with 5-amino-2,4,6-triiodobenzene-1,3-dicarboxylic acid proved 
to be interesting as it changed the unit cell significantly, as described earlier in this 
section.  However, phase information for the complex was not strong enough to locate 
heavy atoms within the unit cell.   
 Another method of experimental phase determination is the preparation of 
selenomethionyl proteins for crystallization. (104)  Production of recombinant protein in 
media containing selenomethionine results in the substitution of the selenium containing 
residue where methionine would normally occur. This method was used to obtain phases 
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for the previously reported NEMO protein containing residues 44 to 111. (72) Initial grid 
screening of selenomethionine 44-195 construct took place around the 17.5 %-25 % PEG 
3350 and 0.1M HEPES 7.5 condition from the native construct. 
2.4 Conclusions and Future Directions 
 In this chapter, a new crystallization condition for reproducible crystallization of 
the 44-195 NEMO construct is described.  The collection of datasets of the NEMO 
crystals reported in this chapter is an important step in the process of creating a method of 
validation for structural study of this interaction. Experimental and computational data 
has been created to assist in the solution of the phase problem for these datasets.  
Crystallization screening selenomethionine substituted 44-195 has been performed.  
Additional quantities of the reported 44-195 crystals can be grown for the preparation of 
seeds with which to seed selenomethionine 44-195 crystal growth. With the solution of 
the crystal construct a platform for validation of fragment-based screening and structural 
investigation of inhibitory compounds can be pursued.  
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CHAPTER THREE 
3.1 PglC Introduction 
3.1.1 Bacterial Glycosylation 
 Glycosylation is a commonly occurring post-translational modification that 
affects a number of processes including protein folding, trafficking, cell-cell interactions 
and host immune response. (105–108)  This modification occurs by a process where a 
number of monosaccharides linked by glycosidic bonds (glycans) are attached to usually 
serine or asparagine residues of a protein.  While glycosylation is well-documented in 
eukaryotes, (109, 110), certain bacteria also possess the ability to glycosylate proteins 
which may improve both survival and pathogenicity.  N-linked glycans in bacteria are 
important for host adherence, invasion and colonization (111).  N-linked glycans are also 
used in the formation of peptidoglycan, the polymer that forms bacterial cells walls.  For 
this reason, disruption of the glycosylation pathway is an attractive target for antibacterial 
therapeutics. 
3.1.2 Campylobacter and Human Diseases 
 Campylobacter jejuni, a microorganism responsible for human intestinal tract 
diseases, synthesizes a heptasaccharide for protein glycosylation, and more than 65 
unique glycosylated C. jejuni proteins have been identified (112).  C. jejuni uses a system 
for biosynthesis of undecaprenyl-diphosphate heptasaccharide containing the unusual 
sugar bacillosamine (2,4-diacetamido-2,4,6- trideoxyglucose)(See Figure 3.1).  Impaired 
glycosylation in C. jejuni results in decreased host adherence and invasion (111, 113), 
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and impaired colonization (111, 113).  The decreased pathogenicity from glycosylation 
interference support the hypothesis that this pathway could be a valuable target for 
treatment of C. jejuni infection as well as related pathogenic bacteria using homologous 
glycosylation pathways including Heliobacter pylori and Neisseria gonorrhoeae. 
 
Figure 3.1: Structure of the bacillosamine sugar in UDP N,N’-diacetylbacillosamine. 
3.1.3 Biosynthetic Pathway of Undecaprenyl-Diphosphate Heptasaccharide 
 The biosynthetic pathway of undecaprenyl-diphosphoate heptasaccharide is 
summarized in Figure 3.2.  The proteins PglF, PglE, PglD, PglC, PglA, PglJ, PglH and 
PglI are found together in the pgl gene locus in C. jejuni and each protein plays a unique 
role in this pathway. (114)  PglF catalyzes the conversion of UDP-N-acetylglucosamine 
(UDP-GlcNAc) to UDP-4-keto- N-acetylglucosamine.  PglE catalyzes the amination of 
UDP-4-keto to UDP-4-amino N-acetylglucosamine and PglD converts UDP-4-amino N-
acetylglucosamine to UDP N,N’-diacetylbacillosamine (UDP-diNAcBac). PglC is a 
phosphoglycosyl transferase that transfers UDP-diNAcBac to undecaprenyl-
pyrophosphate (Und-PP) to become Und-PP-diNacBac. PglA catalyzes the condensation 
of the sugars of Und-PP-diNAcBac and UDP-N-acetylgalactosamine (UDP-GalNAc) to 
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form the disaccharide Und-PP-diNacBac-GalNAc.  PglJ adds the second GalNAc to form 
the trisaccharide, PglH adds the next three GalNAc to form the hexasaccharide and 
finally, PglI adds a single branching glucose residue to form the full glycan: GalNAc-α-
1,4-GalNAc-α-1,4-(Glc-β-1,3)-GalNAc-α-1,4-GalNAc-α-1,4-GalNAc-α-1,3-diNAcBac. 
The flippase PglK then translocates the assembled product to the periplasmic side of the 
inner membrane (115). PglB then transfers the assembled glycan to asparagine residues 
in selected acceptor proteins, resulting in glycosylation (112, 116) 
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Figure 3.2: Pgl Reaction Pathway in C. jejuni  
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 3.1.4 PglC and the Campylobacter glycosylation pathway  
 The phosphoglycosyl transferase PglC is an essential part of this pathway.  PglC 
is a 23 kDa protein with a single predicted TM helix based on the amino acid sequence. 
(117) The protein’s small size,when compared to other phosphoglycosyltransferases such 
as the WecA, MraY and WbaP subfamilies, indicates that it could be the minimal 
catalytic unit required for this reaction which makes it an interesting candidate for 
biophysical characterization (118).  PglC is part of a subfamily of bacterial 
phosphoglycosyltransferases. (119) Therefore, insight into the structure could give us 
information about orthologous structures.  In addition, single transmembrane helix-
containing proteins are underrepresented in the protein databank. (120)  As discussed 
above, interference in this pathway via inhibition of PglC could be a useful therapeutic 
approach. For these reasons PglC is an attractive target for structural characterization. 
 The goal of the research in this chapter is to find a construct of PglC suitable for 
crystallization and to assess the resulting crystallographic data.  To accomplish these 
goals we utilized constructs based on C. jejuni PglC as well as constructs based on 
orthologues of PglC from C. lari (sequence identity: 73%) and C. concisus (sequence 
identity: 72%). Selection of these orthologues is discussed further in the Results and 
Discussion section of this chapter. 
3.2 Materials and Methods 
3.2.1 Refolding of PglC 
 Inclusion body pellets of the soluble domain of PglC from C. jejuni, C. lari and 
C. concisus were provided by Vinita Lukose from the Imperiali Lab at MIT.  The 
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inclusion body pellets were solubilized in 6 M guanidine hydrochloride and adjusted to 1 
mg/mL protein concentration.  The QuickFold Protein Refolding Kit (Molecular 
Dimensions) was used to screen 96 different refolding conditions. (121) 10 µL of 
solubililzed protein was transferred to each well in a 96 well plate and 150 µL total of 16 
different refolding buffers were added sequentially in increasing amounts with 15 minute 
incubation periods between each addition.  After the final addition, the plates were 
incubated overnight at 4° C and the next day 100 uL from each well was added to a 350 
µL AcroPrep™ 96 well filter plate (VWR) with a compatible reception plate (Corning 
3635) to receive the filtrate .  The plate was then centrifuged at 1500 x g for 1 minute and 
the absorbance of the flowthrough measured at 280 nm. Samples from wells with high 
absorbance were examined by SDS gel electrophoresis. 
3.2.2 Characterization of SUMO-PglC by CD 
 To assess the stability of full-length C. concisus PglC, samples were provided by 
Debasis Das from the Imperiali Lab at MIT for characterization by circular dichroism 
(CD). A sample of 40 µM PglC in 50 mM HEPES 7.5, 100 mM NaCl, and 0.03% DDM 
was compared to samples with 120 µM Urea, 5 mM MgSO4 and 0.1% DDM. The CD 
spectra of 300 µL samples were taken in a 0.1 cm path-length cuvette at a wavelength 
range from 200 to 240 nm. 
3.2.3 Crystallization of PglC 
 Preparation of C. jejuni PglC was performed by Meredith Hartley from the 
Imperiali Lab at MIT and provided at a concentration of 1 mg/mL in 50 mM Tris pH 8.0, 
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100 mM NaCl with 0.02% DDM. Initial crystallization attempts were performed with a 
sitting drop vapor diffusion setup at 17° C using the Index, Peg/Ion, PEGRx and SaltRx 
screens in 96 well plates.  Initial screening of this construct did not provide any 
conditions for optimization.  
 Preparation of C. concisus PglC was performed by Vinita Lukose and Debasis 
Das.The protein was provided at a concentration of 6.1 mg/mL in 50 mM HEPES 7.5, 
100 mM NaCl and 0.03% DDM.  Initial crystallization of this construct was perfomed as 
with C. jejuni with the MCSG (Microlytic), Index, Peg/Ion, PegRx, SaltRx (Hampton 
Research), Memgold and Morpheus suite (Molecular Dimensions) of crystallization 
conditions.  These screens were also performed with protein that had been incubated with 
1 mM MgCl2, 1 mM UDP, or both.  PglC containing 1 mM MgCl2 and 1 mM UDP was 
also sent to the Hauptman Woodward Institute 
(www.hwi.buffalo.edu/crystallization/services.html) for additional crystallization 
screening.(122)  Conditions with crystalline material are summarized in Tables 3.1 and 
3.2 and a preliminary crystal condition is shown in Figure 3.3.  These conditions were 
optimized using hanging drop vapor diffusion, sitting drop vapor diffusion, under-oil 
dehydration and capillary gradient crystallization. The final optimized condition is shown 
in Figure 3.4 and was crystallized in a condition of 300–600 mM MgCl2 100 mM Bis-
Tris pH 6.0 and 25-30% PEG 3350 in a hanging drop vapor diffusion format. 
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Table 3.1: Summary of Initial Screening Conditions at Boston University: 
Plate Number/Screen Well/Condition 
Plate 3391 MemGold E11 0.22 M Sodium citrate tribasic dihydrate 0.1 M Tris 8.0 35 
% v/v PEG 400 
Plate 3391 MemGold H8 1.0 M Sodium chloride 0.1 M Sodium citrate 6.0 28 % w/v 
PEG 4000 
Plate 3392 Memgold2 A5 32% PEG 400 0.05 nickel sulfate 0.05 lithium chloride 0.05 
Tris 8.5 
Plate 3392 Memgold2 C12 32% PEG 400 0.1M potassium chloride - 0.1M MES 6 
Plate 3392 Memgold2 E1 0.05 M Sodium sulfate 0.05 M Tris 8.5 35 % v/v PEG 400 
0.05 M Lithium sulfa  
Plate 3392 Memgold2 E11 22% PEG 3000 0.25M magnesium formate - 0.1M Sodium 
Cacodylate 6.5 
Plate 3392 Memgold2 E12 0.1 M Sodium chloride 0.05 M Glycine 9.5 33 % v/v PEG 
300 
Plate 3392 Memgold2 F2 0.12 M Lithium sulfate 0.02 M Tris 7.5 20 % v/v PEG 300 0.1 
M Sodium citrate 5.0 
Plate 3392 Memgold2 F9 32% PEG 400 0.05 sodium chloride 0.04 magnesium 
chloride 0.1 HEPES 7.5 
Plate 3393 Index 82. (G10) 0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-
TRIS pH 5.5, 25% w/v Polyethylene glycol 3,350 
Plate 3393 Index 83. (G11) 0.2 M Magnesium chloride hexahydrate, 0.1 M BIS-
TRIS pH 6.5, 25% w/v Polyethylene glycol 3,350 
Plate 3393 Index 84. (G12) 0.2 M Magnesium chloride hexahydrate, 0.1 M HEPES 
pH 7.5, 25% w/v Polyethylene glycol 3,350 
  
86 
Plate 3393 Index 94. (H10) 0.2 M Sodium citrate tribasic dihydrate, 20% w/v 
Polyethylene glycol 3,350 
Plate 3394 Peg/Ion 5. (A5) 0.2 M Magnesium chloride hexahydrate, 20% w/v 
Polyethylene glycol 3,350 
Plate 3394 Peg/Ion 25. (C1) 0.2 M Magnesium acetate tetrahydrate, 20% w/v 
Polyethylene glycol 3,350 
Plate 3394 Peg/Ion D4 13% PEG 4000 0.2M ammonium sulfate 0.5M ADA 6.5 
Plate 3394 Peg/Ion D6 19% PEG 6000 0.2 sodium chloride - none 0.05 MOPS 7.0 
Plate 3394 Peg/Ion D9 20% PEG 350 MME 0.2 calcium chloride 0.1 MES 5 
Plate 3394 Peg/Ion 66. (F6) 8% v/v TacsimateTM pH 8.0, 20% w/v Polyethylene 
glycol 3,350 
Plate 3395 PegRx Well 17. (B5) 0.1 M Sodium citrate tribasic dihydrate pH 5.5, 
22% w/v Polyethylene glycol 1,000 
 
Table 3.2: Summary of hits from Hauptman Woodward Screening 
HWI3 0.1M Ammonium Phosphate dibasic 0.1M Tris 8.5 PEG 400 20% 
HWI11 0.1 Ammonium Phosphate 0.1M Tris 8.5 PEG 400 36% 
HWI19 0.2M Ammonium Phosphate dibasic 0.1M Tris pH 8.5 PEG 400 28% 
HWI35 0.3M Ammonium Phosphate 0.1M Tris 8.5 PEG 400 10% 
HWI40 0.2M Mg Cl hexahydrate 0.1M MES pH 6.0 PEG 6000 30% 
HWI75 0.05M Ammonium Sulfate 0.1M Sodium Citrate pH 5.6 PEG 2000 25% 
HWI84 0.1M Tris 8 PEG 400 30% 
HWI87 0.2M Ammonium Sulfate 0.1M Sodium Citrate 5.6 
HWI91 0.1M Ammonium Sulfate 0.1M Sodium Citrate 5.6 PEG 2000 25% 
HWI92 0.1M Imidazole pH 7.0 PEGmme 550 25% 
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HWI105 0.1M Ammonium Phosphate 0.1M HEPES 7 PEG 400 36% 
HWI112 0.3M Ammonium Sulfate 0.1M HEPES 7 PEG 6000 20% 
HWI159 0.3M Ammonium Phosphate 0.1M HEPES 7.0 PEG 2000 20% 
HWI169 0.2M Ammonium Sulfate 0.1M Tris 8.5 PEG 4000 20% 
HWI207 0.25M Ammonium Phosphate 0.1M Tris 8.5 PEG 400 14% 
HWI239 0.025M Ammonium phosphate 0.1M Tris 8.5 PEG 400 30% 
HWI274 0.2M MgCl2 hexahydrate 0.1M MES pH 6.0 24% PEG 3350 
HWI300 0.5M KCl 0.1M HEPES 7 PEG 6000 20% 
HWI309 0.25M Ammonium Phosphate 0.1M HEPES 7 PEG 400 25% 
HWI327 0.05M NaCl, 0.1M NaCitrate pH 5.6 PEG 4000 28% 
HWI348 0.05 M CaCl 0.1M Tris 8.2 PEG 400 32% Barium Chloride 0.05 
HWI370 0.1M NaCl 0.1M HEPES 7 PEG 3350 20% 
HWI372 0.1M KCl 0.02M Tris 7 PEG 4000 20% 
HWI442 0.4M MgCl2 0.1M MES 6 PEG 3350 25% 
HWI446 0.4M MgCl2 0.1M MES 6 PEG 3350 20% 
HWI450 0.4M MgCl2 0.1M MES 6 PEG 3350 35% 
HWI459 0.2M Ammonium Phosphate 0.1M Sodium Citrate PEG 2000 16% 
HWI479 0.1M BIS-TRIS 6.5 PEG mme 5000 20% 
HWI486 0.2M NaCl 0.1M HEPES 7 PEG 8000 20% 
HWI502 0.5M NaCl 0.1M HEPES 7 PEG 8000 20% 
HWI504 0.5M NaCl 0.1M HEPES 7 PEG 6000 20% 
HWI530 0.2M NaCl 0.1M HEPES 7 PEG 3350 20% 
HWI531 0.2M NaCl 0.1M HEPES 7 PEG 2000 20% 
HWI546 0.3M NaCl 0.1M HEPES 7 PEG 3350 20% 
HWI547 0.5M NaCl 0.1M HEPES 7 PEG 2000 20% 
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HWI549 0.1M Ammonium Phosphate 0.1M Tris 8.5 PEG 4000 16% 
HWI569 0.3M Ammonium Phosphate 0.1M Tris 8.5 PEG 4000 20% 
HWI632 0.1M Imidazole 7 PEG 6000 20% 
HWI690 0.2M Ammonium Sulfate 0.1M Tris 8.5 PEG 8000 20% 
HWI692 0.2M MgCl2 0.1M Tris 8.5 PEG 6000 20% 
HWI713 0.1M Ammonium Sulfate 0.1M HEPES 7 PEG 400 40% 
HWI732 0.05 HEPES 7.5 PEG 4000 22% 
HWI755 0.3M Ammonium Sulfate 0.1M Tris 8.5 PEG 2000 30% 
HWI758 0.3M Ammonium Sulfate 0.1M Tris 8.5 PEG3350 20% 
HWI761 0.3M MgCl6H2O, 0.1M Tris 8.5, PEG4000 20% 
HWI767 0.1M MgCl2 0.1M Tris 8.5 PEG 2000 20% 
HWI775 0.2M Ammonium Sulfate, 0.1M Tris 8.5, PEG 400 40% 
HWI779 0.2M Ammonium Sulfate 0.1M Tris 8.5 PEG 400 50% 
HWI801 0.05M Ammonium Sulfate 0.1M NaCitrate 5.6 PEG 400 40% 
HWI818 0.2M Lithium Sulfate monohydrate, 0.1M Sodium Citrate pH 5.6, PEG3350 25% 
HWI822 0.2M Lithium Sulfate 0.1M Sodium Citrate PEG 3350 30% 
HWI878 0.2M Ammonium Phosphate 0.1M Tris 8.5 PEG 8000 20% 
HWI894 0.3M Ammonium Phosphate 0.1M Tris 8.5 PEG 8000 20% 
HWI898 0.15M Ammonium Phosphate 0.1M Tris 8.5 PEG 8000 15% 
HWI927 0.2M MgCl26H2O, 0.1M Tris 8.5 PEG 2000 20% 
HWI936 0.2M MgCl26H2O 0.1M Tris 8.5  PEG 4000 25% 
HWI940 0.2M MgCl2 0.1M Sodium Cacodylate PEG 2000 31% 
HWI943 0.4M MgCl26H2O, 0.1M Tris 8.5, PEG 2000 20% 
HWI950 0.4M MgCl26H2O, 0.1M Tris 8.5 PEG3350 20% 
HWI954 0.4M MgCl26H2O, 0.1M Tris 8.5, PEG3350 25% 
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HWI951 0.4M MgCl2 0.1M Tris 8.5 PEG 2000 40% 
HWI954 0.4M MgCl2 0.1M Tris 8.5 PEG 3350 25% 
HWI958 0.4M MgCl2 0.1M MES 6 PEG3350 30% 
HWI959 0.1M Ammonium Phosphate 0.1M Tris 8.5 PEG 2000 20% 
HWI970 0.5M NaCl 0.1M NaCitrate 5.6 PEG 8000 30% 
HWI972 0.5M NaCl 0.1M NaCitrate PEG 6000 30% 
HWI1011 0.5M NaCl 0.1M NaCitrate PEG 2000 20% 
HWI1015 0.5M NaCl 0.1M NaCitrate PEG 2000 30% 
HWI1027 0.05M Ammonium Sulfate, 0.1M HEPES 7, PEG 2000, 20% 
HWI1030 0.05M Ammonium Sulfate 0.1M HEPES 7 PEG 3350 20% 
HWI1065 0.1M CaCl2 0.1M HEPES 7 PEG 400 40% 
HWI1070 0.2M MgCl2 0.1M Tris 8.5 PEG 8000 20% 
HWI1072 0.2M Ammonium Sulfate 0.1M Tris 8.5 PEG 6000 20% 
HWI1079 0.2M Lithium Sulfate monohydrate, 0.1M Sodium Citrate pH 5.6, PEG4000 24% 
HWI1088 0.3M Ammonium Sulfate 0.1M Tris 8.5 PEG 6000 20% 
HWI1107 0.1M Ammonium phosphate 0.1M Tris 8.5 PEG 2000 30% 
HWI1176 0.4M MgCl2 0.1M HEPES 7 PEG 6000 30% 
HWI1177 0.2M KCl 0.1M NaCitrate PEG 400 40% 
HWI1179 0.2M KCl 0.1M Tris 8.5 PEG 400 40% 
HWI1184 0.1M Sodium Phosphate monobasic, 0.1M HEPES 7.0, PEG 6000 20% 
HWI1195 0.4M KCl 0.1M Tris 8.5 PEG 400 40% 
HWI1197 0.4M KCl 0.1M Sodium Citrate 5.6 PEG 400 50% 
HWI1204 0.10% n-Octyl-beta-D-glucoside 0.1M NaCitrate PEG 3350 22% 
HWI1221 0.1M KCl 0.1M HEPES 7 PEG 4000 24% 
HWI1226 0.3M Ammonium Sulfate 0.1M HEPES 7 PEG 3350 30% 
  
90 
HWI1268 0.4M KCl 0.1M Tris 8.5 PEG 6000 20% 
HWI1287 0.3M KCl 0.1M NaCitrate 5.6 PEG 4000 24% 
HWI1387 0.4M NaCl 0.1M Tris 8.5 PEG 400 40% 
HWI1394 0.2M MgCl2 0.1M HEPES 7 PEG 3350 24% 
HWI1395 0.2M MgCl2 0.1M HEPES 7 PEG 2000 30% 
HWI1411 0.4M MgCl2 0.1M HEPES 7 PEG 2000 30% 
HWI1418 0.4M MgCl2 0.1M HEPES 7 PEG 3350 25% 
HWI1422 0.4M MgCl2 0.1M HEPES 7 PEG 3350 30% 
HWI1423 0.1M Ammonium Phosphate 0.1M HEPES 7 PEG 2000 20% 
HWI1461 0.2M NaCl, 0.1M HEPES 7, PEG 400 30% 
HWI1479 0.4M NaCl 0.1M NaCitrate PEG 4000 24% 
HWI1480 0.5M NaCl 0.1M Tris 8.5 PEG 6000 20% 
HWI1507 0.2M NaCl, 0.1M Tris 8.5, PEG 2000 20% 
HWI1520 1M NaCl 0.1M NaCitrate 6 PEG 4000 28% 
HWI1523 0.5M NaCl 0.1M Tris 8.5 PEG 2000 20% 
 
3.2.4 Data collection for C. concisus PglC 
 Datasets for the C. concisus PglC were collected at the Advanced Photon Source 
at the Advanced Photon Source at Beamline 24-ID-E with an ADSC Quantum 315 CCD 
detector. Datasets were integrated and scaled with iMosflm and HKL2000 (123, 124) to a 
resolution of 3 Å with unit cell dimensions of a = b = 71 Å, c = 189 Å, α = β = 90°, γ = 
120°.  Data collection statistics are summarized in Table 3.3. 
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Table 3.3: Data Collection Statistics for PglC 
Dataset ID KNA5_3 KNA5_4 KNA5_5 
Unit Cell 
Dimensions 
71.223 Å 71.223 Å 
189.414 Å 90° 90° 120° 
71.06 Å 71.06 Å 188.55 
Å 90° 90° 120° 
71.22 Å 71.22 Å 
188.91 Å 90° 90° 120° 
Space Group P 3 2 1 P 3 2 1  P 3 2 1  
X-ray source APS 24-ID-E APS 24-ID-E APS 24-ID-E 
Wavelength 0.9792 0.9792 0.9792 
Resolution range 61.68-3.19 (3.41-3.19) 94.28-3.00 (3.18-3.00) 
188.91-3.38 (3.65-
3.38) 
Total/unique 
reflections 
53159/9067 
(9967/1638) 
61582/11672 
(9992/1824) 
43323/8295 
(8993/1653) 
Completeness 93.7 (94.9) 99.9 (100.0) 99.8 (99.9) 
I/sigma 10.3 (1.9) 12.0 (1.9) 8.6 (1.3) 
R-meas 0.247 (1.106) 0.167 (1.115) 0.255 (1.454) 
R-merge 0.225 (1.015) 0.151 (1.008) 0.210 (1.199) 
 
3.3 Results and Discussion 
3.3.1 Identification of PglC Orthologue Suitable for Crystallization 
 Initial crystallization of PglC began with a construct prepared by Meredith 
Hartley of C. jejuni PglC. The construct comprised sequentially (N to C term) a His6 tag, 
a TEV cleavage site, a GB1 tag and PglC (full length, residues 1- 200).  Previous work 
with PglC had been with a construct containing the His6 tag in Triton X-100 detergent, 
but its heterogeneous nature makes it unsuitable for inclusion in a crystallization 
condition due to the purity and monodispersity requisite for crystal formation.  The GB1 
tag was added to improve the expression and solubility of PglC and dodecyl maltoside 
(DDM) was used as a more crystallization-friendly detergent.  However, aggregation of 
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this construct occurred during concentration and the maximum concentration that could 
be reached for initial crystallization attempts was 2 mg/mL.  No crystals were seen in any 
conditions at this concentration and less than 70% of the conditions tested resulted in the 
formation of precipitation, which is an indication that the protein concentration should be 
increased (desired range 75-90% wells precipitate). 
 Attempts to make a more stable PglC construct led to the addition of tags to 
improve the expression and purification profile of the protein.  In addition to the GB1 tag 
a SUMO tag was tried which improved the expression of the PglC construct, but had 
similar aggregation problems as the earlier constructs.  It was hypothesized that removal 
of the transmembrane helix (residues 12-34 in C. jejuni) could produce a construct less 
prone to aggregation. 
 Mutations were made to PglC to remove the transmembrane region of the protein.  
Three constructs, truncated at residue 36, 39 and 42 were prepared with an attached 
SUMO tag and tested for expression and purification.  These constructs were catalytically 
inactive and were expressed primarily in inclusion bodies. 
 Orthologous PglC from C. lari and C. concisus were identified via sequence 
identity by Vinita Lukose and confirmed to use the same substrate as C. jejuni PglC (data 
not shown).  Hydropathy plots of the predicted structure of all three PglC orthologues 
indicates that the C. jejuni orthologue contains an additional predicted hydrophobic 
region in addition to the transmembrane helix that could also be responsible for the 
aggregation difficulties faced during purification and concentration, as shown in Figure 
3.5.  (117) 
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Figure 3.3: Hydropathy plot of C. jejuni PglC (A), C. lari PglC (B), C. concisus PglC (C) generated with the 
TMHMM server (117). 
The probability that each residue is included in a transmembrane helix is plotted against residue number.  The 
box highlights a hydrophobic section of PglC from C. jejuni. [Analysis performed by Vinita Lukose] 
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 All three transmembrane helix-removed constructs of PglC were prepared but 
expression remained a problem as most recombinant protein was found in inclusion 
bodies. Vinita Lukose provided inclusion body pellets to the Allen lab for refolding 
attempts.  A number of different buffers and additives were tested for the ability to 
promote refolding of protein isolated from these inclusion bodies in a high-throughput 
manner.  Hits from this initial refolding screen were scaled up and refolding on a His6 tag 
affinity column was attempted.  None of the initial hits produced refolding of PglC in 
amounts suitable for crystallization experiments. 
 Based on the poor expression profiles of the transmembrane helix-removed PglC 
constructs, expression was attempted with full length C. lari and C. concisus with an 
added SUMO tag by Debasis Das.  The C. lari construct had better expression and 
reduced aggregation compared to previously studied PglC constructs and, after adding a 
SGSG linker between the construct and the SUMO tag, the SUMO domain could be 
removed successfully.  This protein was provided for crystallization at a concentration of 
6 mg/mL. 
3.3.2 Circular Dichroism Spectra of PglC 
 Planning the initial crystallization conditions including making the decision of 
which additives from the initial crystallization conditions (comprising urea and MgCl2), 
should be included in crystallization of PglC.  The CD spectra of PglC (plus 0.015% 
DDM) with the sequential addition of urea, MgCl2, and increased DDM was measured to 
investigate the effect of these additives on the secondary structure and melting 
temperature (data not shown).  None of the additives resulted in a significant stabilization 
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of the protein. However, neither was PglC significantly destabilized by any of these 
additives, which would have been an indication not to include these additives in 
crystallization experiments.  Urea, MgCl2 and additional DDM were left out of 
crystallization conditions after initial hits indicated they were not needed for crystal 
formation.  UDP was included in all crystal conditions and crystals were not observed in 
its absence. 
3.3.3 Initial and Optimized Crystallization Conditions 
 Crystallization trials on full length C. lari PglC were performed using a number of 
high throughput screens (MCSG, MemGold, Morpheus, Index, PegRx, SaltRx, Peg/Ion) 
in house and at the HWI using the membrane screening facility.  The Hauptman-
Woodward membrane-screening facility includes 1536 microbatch-under oil 
crystallization conditions  There were a large number of initial conditions that had 
crystalline material, so a subset of overlapping conditions shown in Table 3.4 were 
selected for optimization screening.  After scaling up from microbatch, crystals were only 
observed in the presence of UDP and in wells containing greater than 100 mM 
magnesium and with PEG 3350..  Optimization of this MgCl2/PEG3350 condition 
resulted in the final condition: 300–600 mM MgCl2 100 mM Bis-Tris pH 6.0 and 25-30% 
PEG 3350 set up in a hanging drop vapor diffusion format with 6.1 mg/ml protein and 2 
μl protein plus 2 μl well. Crystals were grown at 17° C in ~3 days to a typical dimensions 
of 100 mm x 100 mm x 30 mm.  
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Table 3.4: Overlapping Crystal Conditions 
Condition 
HEPES/MgCl2/PEG3350 
HEPES/MgCl2/PEG2000 
MES/MgCl2/PEG3350 
Bis-Tris/MgCl2/PEG3350 
Citrate/PEG3350/Urea 
Citrate/LiSO4/PEG3350 
Citrate/NH4SO4/PEG2000 
Citrate/NaCl/PEG4000 
Citrate/KCl/PEG400/Urea 
Citrate/NaCl/PEG2000/Urea 
 
3.3.4 PglC Diffraction Screening 
 The PglC crystals grown under the optimized condition were screened for 
diffraction but crystal manipulation, cryo-cooling and reproducibility of diffraction 
proved to be a significant challenge.  Initial observation of diffraction and data collection 
was performed on the Rigaku MicroMax-007HF X-ray generator with VariMax-HR 
optics, an R-AXIS IV++ imaging plate detector and the Oxford Cryosystems 
Cryostreams 700 at Northeastern University. To test diffraction, a room temperature 
capillary sleeve was utilized to keep the crystal hydrated during X-ray exposure.  
Collection of a dataset was attempted but diffraction quality decreased rapidly from 
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approximately 3 Å to greater than 20 Å after several minutes of data collection.  Other 
crystals from the same well showed no diffraction using the same mounting method.  A 
number of cryoprotectant solutions were investigated during crystal screening including 
PEG 400, MPD, glycerol, and ethylene glycol, glucose and Paratone-N.  Paratone-N, 
PEG 400 and glycerol were effective in reducing the presence of ice in the sample, but no 
diffraction was observed in any cryo-protected sample.  Conditions with high PEG 3350 
concentration (greater than 30%) that did not require transfer to a cryoprotectant solution 
resulted in crystals that showed some low resolution diffraction, which may indicate that 
transfer to the cryoprotectant solution is disrupting crystal order. Careful crystal 
manipulation and many replicate screening attempts were necessary to reproducibly 
mount well-ordered and crystals that diffracted to high resolution. 
 
Figure 3.4 Crystals of PglC: 0.1M HEPES 7.5, 0.2M MgCl2, 25% PEG 3350 
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Figure 3.5: Optimized Crystals of PglC: 100 mM Bis Tris 6, 300 mM MgCl2, 29% PEG 3350 
 
3.3.5 Post-Crystallization Modification 
 In an attempt to improve the diffraction quality of the crystals being studied, 
several methods of post-crystallization modification were tried.  Glutaraldehyde cross-
linking was used to lightly fix the crystal morphology and minimize any distortion from 
the process of mounting in cryo loops and freezing.  Many crystals were found to diffract 
pooly (between 8-15 Å resolution) and different cryo-annealing methods were used to try 
to improve this diffraction to a resolution more suitable for structure determination.(125)  
We posited that changes in hydration may explain the loss of diffraction upon 
manipulation (mounting) of the crystals.  Thus, different salt solutions were used to 
change the hydration level of the crystal prior to screening. While these modifications did 
not prove successful in increasing the number of diffracting crystals, the hypothesis that 
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disruption of the crystallization well decreases the quality of the PglC crystals led to the 
method that ultimately resulted in the successful collection of PglC datasets. 
3.3.6 PglC Data Collection 
 The method used to produce crystals of PglC for data collection was the 
replication of a single crystallization condition (100 mM BisTris 6.0, 300 mM MgCl2 
25% PEG3350) in a sitting drop format within a 96 well plate.  Each of these wells is 
sealed by sealing film that allows the crystals to grow undisturbed.  When the crystals 
were harvested for screening, each well could be opened separately without disturbing 
the surrounding wells.  In this way, PglC crystals could be harvested and frozen without 
cryoprotection in liquid nitrogen rapidly after opening the well allowing for repeated 
harvesting of minimally disturbed crystals.  Over 50 PglC crystals were cryo-cooled in 
this way for screening at APS. Crystals were the same size and shape of the optimized 
crystals reported earlier in this section (100 µm x 100 µm x 30 µm).  Diffraction was 
observed in 4 crystals to ~ 3 Å and of these, 3 datasets were processed successfully.  
These datasets share the same unit cell as the crystal previously screened at room 
temperature at Northeastern. 
3.3.7 Phasing of PglC 
 Identification of a molecular replacement search model to obtain phases for the 
datasets of PglC is a challenging prospect due to the lack of homologous structures 
available in the PDB.  This lack of sequence similarity to proteins of known structure 
makes homology modelling intractable.. Computationally predicted models of C. jejuni 
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PglC were provided by Lingqi Luo (Allen Lab, BU) for use as search models. These 
search models were created by the I-TASSER server and the EVFOLD server.  I-
TASSER generates the full-length model from multiple threading alignments from 
structures in the PDB and then undergoes a process of iterative structural assembly 
simulations and refinement. (126) In this case structural restraints were added in I-
TASSERusing residue pairs determined from analysis of conservational covariance, The 
EVFold server also calculates a set of co-evolved residue pairs in a protein family and 
predicts protein folding using constraints on the distances between those pairs. (127)  
Additional search models were generated using AMPLE, a cluster-and-truncate approach 
for generating search models based on ab initio models (in this case based on short poly-
alanine helices) but a molecular replacement solution has not yet been found. (126–128) 
 Along with the attempted molecular replacement solutions, modifications to PglC 
and the crystal conditions were made to allow for the possibility of experimental phasing.  
The addition of methionines was undertaken to increase the sulfur content of PglC for 
sulfur single wavelength anomalous dispersion (SAD).  Constructs of C. concisus PglC 
were prepared by Debasis Das that incorporated methionine residues found in 
isofunctional orthologues as shown in the sequence alignment in Figure 3.7. Two double 
mutant constructs were prepared: I64M/I94M and I64M/Q182M and will be set up for 
crystallization screening.  In addition to variant construct preparation, iodo-UDP will be 
obtained for co-crystallization for phasing using single isomorphous replacement and 
using the anomalous signal from Iodine. 
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Figure 3.6: Sequence Alignment of PglC Orthologues. 
Residues highlighted with the dashed box were selected for mutation. 
3.4 Conclusions and Future Work 
 To summarize, significant progress has been made in investigating conditions and 
protein constructs suitable for structural determination of PglC.  Crystals of a C. concisus 
PglC (residues 1-201) have been reproducibly produced and observed to diffract to ~3 Å.  
Datasets containing heavy atom soaked PglC have been collected for experimental 
determination of the phases for structure solution. Determination of the structure will 
contribute to the understanding of underrepresented single transmembrane helix proteins, 
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the minimal catalytic unit of the phosphoglycosyl transferase reaction and provide the 
structural basis for antibacterial therapeutics. 
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APPENDIX: A1 
A1.1 Introduction 
A1.1.1 Haloacid Dehalogenase Superfamily 
 The haloacid dehalogenase (HAD) enzyme superfamily has over 120,000 
identified members which are found in organisms ranging from bacteria to humans.  The 
superfamily is named after 2-haloalkanoate dehalogenase but the majority of enzymes in 
this family catalyze phosphoryl transfer. (129)  The active-site residues involved in the 
reaction mechanism are found in four motifs in the primary protein structure and are well 
conserved across family members.  These motifs are located on loops in the Rossmannoid 
fold that makes up the 'core' domain of HAD superfamily enzymes, shown in Figure 
A1.1, using the structure of BT4131, a hexose phosphate phosphatase as an example. 
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Figure A1.1: HAD active site representation.   
(Top) Schematic representation of the typical HAD active site.  (Bottom)  The topology of the Rossmann fold.     
 In the HAD superfamily these conserved catalytic motifs form the active site and 
also comprise a binding site for a conserved metal ion (Mg2+). Figure A1.1 (A) shows a 
generalized depiction of the Rossmann fold loops and identifies residues responsible for 
Mg2+ and phosphoryl group binding and the generation of substrate specificity.  Loop 1 
contains a nucleophilic aspartate, a general acid/base catalyst and the backbone carbonyl 
responsible for magnesium cofactor binding (the depiction of Figure 2a is a two-
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dimensional representation of a three-dimensional active site, the aspartate residues in 
this loop are only separated by one amino acid); Loop 2 has a serine or threonine that 
coordinates the phosphoryl group, as does the lysine or arginine of loop 3; in the 
members performing phosphoryl transfer Loop 4 coordinates the magnesium through two 
aspartate or glutamate residues, sometimes through a bridging water. 
 The HAD superfamily is divided into families based on the topology and location 
of inserts, termed 'caps', found in the Rossmann fold. There are three main types of cap 
families: C0, C1 and C2. Type C0 members have a minimal cap, or lack a cap entirely. 
Type C1 members have a cap comprised of α-helices found between motifs 1 and 2. Type 
C2 have an insert between motifs 2 and 3 and have one of two different α/β domains. The 
cap domains usually contribute to substrate specificity by binding the leaving group.(130)  
The phosphate group is involved in a diverse set of biochemical functions essential to cell 
growth and adaptation. It has numerous functions, such as metabolite solubility, 
membrane transport, and on/off switching for signal transduction. Phosphate also plays a 
direct role in metabolic processes, such as mineralization. 
 Human PHOSPHO1 (hP1) is a 29.5 kDa phosphatase in the HAD superfamily.  
The enzyme action increases the concentration of phosphate in matrix vesicles, resulting 
in the precipitation of calcium phosphate.(131) This process is found in pathological 
mineralization as well as in the normal formation of bone, cartilage, and teeth.(132) hP1 
cleaves a phosphoryl group from either phosphoethanolamine or phosphocholine using a 
Mg2+-dependent mechanism shared by other HAD superfamily phosphatases.(133) 
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PHOSPHO2 (hP2), another human phosphatase in the HAD superfamily, shares 
significant sequence similarity (42%) but has different substrate specificity.(134)   
 hP1  shares the same catalytic motifs characteristic of the HAD superfamily on 
the basis of primary sequence alignments.(135)  Site-directed mutagenesis of active-site 
residues Asp32 and Asp203 of hP1 (Figure A1.2), found in motifs 1 and 4, respectively, 
resulted in a complete loss of activity, indicating that the enzyme uses the same Mg2+-
dependent mechanism as other HAD phosphatases.(131) Asp43 and Asp123 located near, 
but not in  motifs 1 and 2 in the amino acid sequence are conserved in hP1 and its 
orthologues, and are implicated in binding to the cation portion of the substrate and 
providing the enzyme its substrate specificity. This feature is not shared by other 
phosphatases in the HAD superfamily and sets it apart as a member of a novel group. 
 
Figure A1.2: Active site in homology model of PHOSPHO1.   
Residues comprising the HAD active-site motif 1 (red), motif 2 (green), motif 3 (blue), and motif 4 (yellow) are 
shown as sticks. 
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 hP1 was first discovered in 1999 when its encoding gene was found to be 
expressed at very high levels in chicken growth plate chondrocytes.(136) Chicken 
PHOSPHO1 (gP1), as well as its orthologues in humans and mice, was identified as a 
putative phosphatase based on the cleavage of p-nitrophenyl phosphate. The expression 
of gP1 in chondrocytes suggested a role in phosphate production for matrix 
mineralization.(136) 
 There is growing evidence supporting the role of matrix-vesicle mineralization, 
and thus the importance of PHOSPHO1, in pathological as well as physiological 
hydroxyapatite deposition.  Deficiency of phosphate production in skeletal tissue ranges 
in phenotype from premature loss of teeth to death in utero.(137) Inhibition of gP1 with 
lansoprazole, a small molecule inhibitor of PHOSPHO1 activity, was shown to impair 
skeletal mineralization in developing chick embryos.(138)  Abnormal calcification and 
calcium phosphate crystals were found in the synovial fluid of patients with crystal 
deposition diseases such as calcific tendonitis and Milwaukee Shoulder Syndrome.(139)  
Matrix vesicles isolated from patients with osteoarthritis were more prone to initiate in 
vitro calcification.(140) Pathological mineralization is linked to osteoarthritis, crystal-
deposition arthritis, and tumor calcification in breast cancer but the role of this process in 
the diseases are still not well understood.(141, 142)  The development of inhibitors of this 
process would give additional information into the pathway and could become an 
effective intervention to abnormal crystallization events. 
  A homologous protein PHOSPHO2 has been recently identified that shares a 
high sequence identity but lacks affinity for the substrates of PHOSPHO1 (Figure A1.3),   
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including phosphoethanolamine or phosphocholine, instead catalyzing the hydrolysis of 
pyridoxal-5-phosphate and other organophosphates (Figure A1.4).(134) While the 
kinetics have been studied, there are additional substrates for both of those enzymes for 
which the catalytic efficiency has not yet been reported.  Activity has been measured both 
with a discontinuous colorimetric assay and a continuous spectrophotometric coupled 
assay.(133)  
 
Figure A1.3: Substrates of Phospho1.   
A:  Pyridoxal-5-Phosphate B: Phosphocholine C: Phosphoethanolamine D: Ribose-5-phosphate E: p-nitrophenyl 
phosphate F: β-glycerol phosphate (134) 
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Figure A1.4: Substrates of PHOSPHO2 (Roberts 2005) 
 Uncharacterized HAD proteins from the Enzyme Function Initiative (EFI), listed 
as EFI identifier 501217, 501314, and 502337 (Gerlt et al., 2011) also share some 
overlapping activity with PHOSPHO1 and PHOSPHO2. These proteins are similar to one 
another with a 37.5% sequence identity between 501217 and 501314 and a 40.0% 
sequence identity between 501314 and 502337.  501217 is a hydrolase in Psuedomonas 
putida, a Gram-negative soil bacterium with a mass of 25.3 kDa. 501217 has a 5 carbon 
acid sugars phosphatase activity. 501314 is a phosphatase in Bacillus halodurans, a 
Gram-positive soil bacterium with a mass of 30.7 kDa and uses phosphoethanolamine as 
a substrate, as does PHOSPHO1. 502337 is a sugar phosphatase in Cytophaga 
hutchinsonii, a Gram-negative soil bacterium with a mass of 31.3 kDa that uses 
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phosphocholine as a substrate, as does PHOSPHO1. This overlapping activity may form 
the basis for similar structures and functions amongst the five proteins. 
 The novel substrate specificity of these enzymes in the HAD superfamily and 
their role in biological processes make the group a logical candidate for structural 
determination as a basis for investigation as to their biological function at the molecular 
level.   In this Appendix the progress made in characterizing these proteins is reported. 
A1.2 Materials and Methods 
[Work in the section done in collaboration with undergraduate research assistant Kelly 
Huynh] 
A1.2.1 HAD Constructs 
 Purified human hP1 was obtained from Hua Huang and Liangbing Wang for the 
crystallization attempts discussed in this section.  The cDNA encoding hP1 was amplified 
by PCR using Pfu DNA polymerase.  Oligonucleotide primers containing restriction 
endonuclease cleavage sites NdeI and XhoI were used in the PCR reactions.  The pET-
23a vector, cut by the same restriction enzymes, was ligated to the PCR product that was 
isolated.  The ligation product was used to transform competent E. coli BL21 (DE3) cells 
and the plasmid DNA was purified using a Qiaprep Spin Miniprep Kit and ligation 
confirmed by DNA sequencing. 
 Alternative constructs of hP1 were created to prepare an inactive form of the 
protein for co-crystallization with substrate and to improve the crystallization properties 
of the protein. The pet23-a vector was used as a template to introduce active site Asp to 
Ala mutations (D32A and D34A) using a protocol based on the Quick Change site-
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directed mutagenesis kit using iProof polymerase, forward and reverses primers and 
digestion with DpnI.  The SERp Server identified additional mutations that could produce 
protein that will crystallize more readily by the surface entropy reduction approach.(143)  
Three clusters of residues were found in the hP1 sequence that could promote 
crystallization: Q235A-K237A-E239A, K111A-Q112A and E35A and these were 
prepared similarly to the active site mutants.  The codon-optimized gene of hP1 was also 
obtained from Genewiz and inserted into the the plasmids pDONR221, pDEST17, 
pDEST14, pDEST-SUMO and pDEST-His-MBP using the Gateway system. 
 Gallus gallus PHOSPHO1 and PHOSPHO2 (gP1, gP2) were synthesized by 
Genewiz in a pUC57-Amp vector and codon optimized for E. coli. The genes were 
synthesized with attB flanking sequences and tagged with TEV.  The genes were inserted 
into expression vectors via BP and LR reactions by Gateway Cloning. 
 501217, 501314, and 502337 were supplied in plasmids via the EFI. 501217, 
501314, and 502337 are in pSGC-His plasmids. 501314 and 501217 were transformed 
into separate Rosetta 2(DE3) expression cells with the same transformation protocol used 
for GP1 and GP2. The strain BL21 (DE3) was also transformed with 501217, 501314, 
and 502337. 
 The plasmids of all proteins were transformed into the XL-10 Gold, BL21 (DE3), 
BL21 pLysS, BLSTAR (DE3), B834, SoluBL21 and ArcticExpress(DE3) cell strains for 
storage and expression.  Cells were grown in LB broth with proper selection antibiotics 
and then induced with IPTG. Cells were harvested by centrifugation and lysed via either 
lysozyme or microfluidizer.  Expression was determined via SDS-PAGE in small volume 
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text expressions before scaling up to larger preparations (See Table A1.1 for detailed 
expression and solubility data).   
A1.2.2 Purification 
 The method for purification of hP1 as determined by Hua Huang is as follows. 
Transformed cells (10 L) were grown at 37 °C with agitation at 200 rpm in Luria broth 
containing 50 µg/mL ampicillin to an OD600 of 0.6-1.0 and then induced for 10 h at 18 °C 
at a final concentration of 0.4 mM isopropyl a-D-thiogalactopyranoside (IPTG). The cells 
were harvested by centrifugation (6500 rpm for 15 min at 4 °C) to yield 3 g/L of culture 
medium. The cell pellet was suspended in 1 g wet cell/10 mL of ice-cold buffer A 
consisting of 50 mM Tris (pH 8.5 at 25 °C), 5 mM MgCl2 and 1 mM dithiothreitol 
(DTT). The cell suspension was passed through a French press at 1,200 PSIG before 
centrifugation at 20,000 rpm and 4°C for 60 min. The supernatant was fractionated by 
ammonium sulfate induced protein precipitation. The 0–50% ammonium sulfate protein 
precipitate was dialyzed three times at 4 °C against 2 liters of Buffer A before loading 
onto a 40 ´ 5 cm Q-sepharose column, which was eluted with a 2 L linear gradient of KCl 
(0 to 0.5 M) in buffer A. The column fractions were analyzed by SDS-PAGE. The 
desired fractions were combined, concentrated at 4 °C with an Amicon concentrator 
(Amicon) to 25 mg/mL.  The resulting sample was concentrated using a MACROSEP 
10K OMEGA for storage at -80 °C. The protein sample was shown to be homogeneous 
by SDS-PAGE analysis with a yield of 10 mg of protein/g wet cell.  This protein was 
used in the initial crystallization trials discussed later in this section. 
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Table A1.1: Summary of Expression and Purification of HAD members. 
Expression and solubility of PHOSPHO1 and PHOSPHO2 orthologues in various cell strains and vectors. 
Vectors that did not sequence or transform correctly and cell strains with no expression are not included in this 
list. 
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 To increase the yield of hP1, additives and inclusion body refolding were 
investigated. Stabilizing additives trehalose, glycine betaine, and potassium citrate were 
added to the lysis step, as recommended in Leibly, et al.(144)  Inclusion body pellets 
were prepared via lysis with lysozyme followed by ultracentrifugation at 20,000 x g for 
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20 minutes at 4 °C.  The pellet was resuspended in a wash buffer containing 1% Triton 
X-100 and washed several times before a final wash without detergent and then spun a 
final time.  The hP1 pellets were solubilized under denatured conditions in guanidine HCl 
and urea and refolding was attempted in a high-throughput format with the QuickFold 
Protein Refolding Kit (Molecular Dimensions).  The samples were passed through an 
AcroPrep Advance 96 Multi-Well Filter Plate (VWR) and the concentration of the 
refolded protein was measured at A280.  Large scale preparations of the indicated 
conditions were made but no retention of protein was observed on a 5 mL His-trap FF 
column.  Molecular weight analysis via SDS –PAGE indicated that other proteins in the 
inclusion body pellet were being refolded in each condition. 
 The expression vectors for hP1, hP2, gP1 and gP2 were transformed into Arctic 
Express (DE3) expression cells. Between 100 ng – 150 ng of DNA were added to 50 μL 
of competent expression cells and placed on ice for 30 minutes. The cells were then heat-
shocked at 42 °C for 30 seconds and then placed back on ice for 10 minutes. Then, 250 
μL of SOC media were added to the cells and incubated at 37 °C for 1 hour. The treated 
cells were plated onto a LB plate with the required antibiotic and incubated at 37 °C 
overnight. The selection of antibiotics is determined by the expression vector.  The cells 
were grown in LB media with 100 μg/mL of carbenicillin at 37 °C until the OD600 > 0.4 
and induced with a final concentration of 1 mM IPTG. The cells were then incubated at 
16 °C for 24 hours. The cell solution was then centrifuged at 5000 rpm for 10 minutes at 
4 °C. The cell pellet was collected and stored in 50 mL conical vials at -80 °C.  The cell 
pellet was thawed and resuspended in 25 mM Hepes pH7.5, 5 mM MgCl2, 100 mM 
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NaCl, and 1 mM DTT. A 10 μg/mL sample of DNase and a SIGMAFAST Protease 
Inhibitor Cocktail Tablet are also added to the buffer.  The cells were then lysed via 
microfluidization (once at 18,000 psi), ultracentrifuged (38,000 rpm for 30 minutes at 4 
°C), and purified over a GE 5 mL HisTrap HP Column packed with Ni Sepharose High 
Performance resin. GP1 was loaded onto the column with 25 mM Hepes pH 7.5, 500 mM 
NaCl, 2.5 mM MgCl2, and 20 mM imidazole. GP1 was eluted from the column with 50 
mM Hepes pH 7.5, 500 mM NaCl, 2 mM MgCl2, and 250 mM imidazole. The optimal 
buffers were determined via a Thermofluor assay.(145) 
 501314 and 501217 were transformed into separate Rosetta 2(DE3) expression 
cells with the same transformation protocol used for gP1 for gP2. 501217 and 501314 
were separately grown in LB media with 50 μg/mL of kanamycin at 37 °C until OD600 > 
0.4 and induced with a final concentration of 1 mM IPTG. The cells were incubated for 
24 hours at 16 °C. The cell solution was then centrifuged at 5000 rpm for 10 minutes at 4 
°C. The cell pellet was collected and stored in 50 mL conical vials at -80 °C.  The cells 
were lysed via microfluidization (twice at 18,000 psi), ultracentrifuged (38,000 rpm for 
30 minutes at 4 °C), and purified over a GE 5 mL HisTrap HP Column packed with Ni 
Sepharose High Performance resin. The proteins were lysed, bound, and eluted in the 
same buffer conditions as gP1. A thermofluor assay was used to confirm buffer 
conditions for 501314.(145) Sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
(SDS-PAGE) at 15% were used to image the cells during growth, induction, and 
purification. Best expression for hP1, hP2, gP1, and gP2 was observed with the pDEST17 
vector in Artic Express (DE3). The construct that resulted in the most purified soluble 
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protein was hP2 when successfully scaled up and purified with an average of 0.2 mg/L of 
soluble protein at 90% purity. 
A1.2.3 HAD characterization 
 The Biomol Green assay was used to identify or confirm enzyme activity with 
substrate by measuring the amount of free-phosphate in solution. A 10 μM sample of 
protein was incubated with 1 mM of various substrates for 20 minutes at room 
temperature in a microplate. Then, 100 μL of Biomol Green Reagent was added and 
incubated at room temperature for 20 minutes. The plate absorbance was read at 620 nm 
and compared to a standard curve and a control plate containing only buffer.  The wells 
with the greatest change in absorbance indicate activity with the substrate in the well.   
 This same method was used to measure activity of 501314 in a discontinuous 
assay with Biomol Green. 501314 (10 μM) was added to a well along with 0.5 mM 
phosphoethanolamine in purification buffer to a total volume of 50 μL.  After 20 minutes 
incubation at room temperature, 100 μL of Biomol Green Reagent was added to each 
well. The absorbance at 620 nm was read to determine how much free phosphate was in 
solution. 
 Thermofluor experiments were carried out using a Realplex EP Mastercycler RT 
PCR. 1 mL of 20 µM hP1, hP2 and 501314 with 1 µL of 5000x Sypro Orange dye was 
prepared and 10 µL of this protein solution added to each well of a 96 Eppendorf white 
well plate along with 10 uL of buffer solutions in a pH range of 3 to 10 along with 100 
mM NaCl and 5% glycerol as additives.(46)  The plate was sealed with clear seal film to 
prevent evaporation. The plate was inserted into the RT-PCR machine and heated at a 
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rate of 1 °C per minute.  Fluorescence was measured at 520 nm and the temperature of 
melting defined as the midpoint of the peak of the change in fluorescence intensity over 
time.  The crystallization screens of hP2 described in this section were performed with 
the buffers HEPES 7.5, Tris 7.5, MOPS 7.0 as these were the optimal buffers determined 
using the thermofluor screen. 
 A Superdex 75 10/300 GL column was used for gel filtration of 501314. A 500 
µL sample of 1.45 mg/mL was loaded onto a column equilibrated with a buffer 
containing 50 mM Hepes pH 7.5 and 150 mM NaCl and run through the column at 0.5 
mL/min. Prior to initial crystallization, frozen protein was thawed on ice and the 
polydispersity of 20 µL of a 1 mg/mL solution checked by dynamic light scattering on a 
Protein Solutions DynaPro instrument and interpreted with the Dynamics software 
package.  Protein samples with less than 25% polydispersity were used for crystallization 
trials. 
A1.2.4 Crystallization 
 PHOSPHO1 was crystallized using hanging-drop or sitting-drop vapor 
diffusion.  Crystal conditions were screened at varying temperature and concentration. 
Primary crystallization screens, including Index Screen, Crystal Screen, PEG/Ion, and 
Additive screen purchased from Hampton Research were used to find crystallization 
conditions for PHOSPHO1. Table A1.2 lists a subset of primary crystallization screens 
that were used to find crystallization conditions.  Crystal growth was observed in 0.1M 
BIS-Tris from pH 5.5 - 6.5 and containing either PEG 3350 or PEG MME 5000. These 
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crystals (shown in Figure A1.5) diffracted to 2.8 Å on the home source at room 
temperature. 
Table A1.2: hP1 Primary Screens  
Commercial 
Screens 
Buffer  Temperature 
(oC) 
Concentration 
(mg/mL) 
Other 
Index Tris 8.5 4 1 Microseed 
PEG/Ion Tris 7.5 17 5 Matrix 
Microseed 
PEG/Ion 2 HEPES 
7.5 
25 10 Cryo 
Crystal Screen HEPES 
7.0 
 15 Tungstate 
Crystal Screen 
2 
BIS-Tris 
6.5 
 20 Vanadate 
PEG/Rx BIS-Tris 
5.5 
 25 PEG 
Optimization 
Additive MOPS 7.0  30 Glutaraldehyde 
Silver Bullet    Glycerol 
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In order to collect a full dataset on these crystals, various cryoprotectants were 
tested.  Co-crystallization was attempted with PEG 400, MPD, glycerol, and ethylene 
glycol without success.  Crystals were soaked with PFO, PEG 400, MPD, glycerol and 
ethylene glycol before identifying paratone-N as the best cryoprotectant based on the 
diffraction observed after cryoprotection. 
 With the addition of cryoprotectant, the resolution limit of diffraction of the 
crystals decreased to 8 - 10 Å and the crystals demonstrated a high amount of variability 
in diffraction quality.  Based on this data and visual inspection of the crystal during 
cryoprotectant soaking, it was likely that the viscosity of the cryoprotectant was 
damaging the crystal packing.  Glutaraldehyde was then use to crosslink the crystal to 
increase its stability during this process.  Before cryoprotection, the drop containing the 
crystals was sealed in a well with a 0.5-2% glutaraldehyde in solution.  Various 
concentration of glutaraldehyde and exposure times were tested to find the optimal 
parameters.  With the crosslinking for 20 minutes with a 1% glutaraldehyde solution, the 
diffraction of the crystals improved to 2-3 Å.   
 To aid in phasing of the hP1 structure, vanadate and tungstate were added to the 
crystallization condition at concentrations from 0.1 – 5 mM.  Soaking of glutaraldehyde 
cross-linked crystals in stabilizing solutions containing 10 mM vanadate or tungstate was 
also attempted.   
A1.2.5 Data Collection 
 Crystals were harvested and flash-cooled to 100 K using liquid nitrogen cooled 
gaseous nitrogen.  Data was reduced using SAINT (Bruker) and scaled using AXS from 
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the Proteum2 software suite (Bruker) Data was collected on a Bruker Microstar CuKα 
and a Platinum 135 CCD detector.  Data collection statistics for the highest resolution 
dataset are provided in Table A1.3. 
Table A1.3: Data Collection Statistics for PHOSPHO1 
Detector distance (mm) 89.0 
Exposure time (s) 300 
Wavelength (Å) 1.54178 
Oscillation (°) 0.5 
Scans  
Phi 136 frames 
Omega 338 frames 
Resolution (Å) 33.36-2.37 (2.457-2.37) 
Space group P222 
Unit-cell parameters  
a (Å) 33.3 
b (Å) 78.7 
c (Å) 89.4 
alpha (°) 90 
beta (°) 90 
gamma (°) 90 
Unique reflections 14444 
Average redundancy 3.12 (1.68) 
Completeness 84.9 (15.3) 
Mean I/sigma 6.98 (3.48) 
Rint 0.1819 (0.2976) 
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A1.2.6 Homology Modeling 
 Phyre2 was used to predict structures for each protein based on sequence 
alignment with known structures in the PDB.(99)  The amino acid sequences of hP1, hP2, 
gP1, gP2, 501217, 501314, and 502337 were uploaded and models generated with the 
intensive modeling mode. 
A1.3 Results and Discussion 
A1.3.1 Crystallization of PHOSPHO1 
 Initial high-throughput screening of hP1 provided by Hua Huang resulted in the 
formation of needle crystals (depicted in Figure A1.5).  Additional screening and 
optimization was performed to try to alter the morphology of the crystals into a 
morphology less prone to shearing during crystal manipulation was unsuccessful.  
Glutaraldehyde cross-linking provided enough stability to allow for collection of a 
dataset at 2.4 Å resolution. 
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Figure A1.5: Crystals of hP1 in 0.1M Bis-Tris 6.5 25% PEG 3350 
 PROTEUM (Bruker) was used to merge and scale datasets.   Molecular 
replacement was attempted with a hiomology model based on the structure of 
phosphoserine phosphatase (PSP) and others with suitable sequence identity and 
secondary structure similarity.  Protein sequence prediction using the program PHYRE 
has identified several HAD phosphatases (PDB ID: 2HSZ: 18%, 2HDO: 14%, 1TE2: 
14%) that were used to attempt molecular replacement, in addition to the structure of 
phosphoserine phosphatase used previously to construct the homology model.(146)  In 
addition, phenix.ensembler was used to create ensembles of structures to use as molecular 
replacement search models.(147)  Molecular replacement with PHENIX failed to result in 
a suitable solution. 
 Vanadate and tungstate, inhibitors of other HAD members, were investigated as 
possible ligands for hP1.  Vanadate and tungstate form a pentacovalent coordination 
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complex with trigonal bipyramidal geometry to provide a structural understanding of the 
interactions similar to those between active site residues and substrate during the 
transition state.  These ligands were cocrystallized with the protein and crystals of the 
native protein were soaked in a solution containing ligand. Incomplete phasing 
information from a tungstate-soaked crystal was collected at the home source to 3.0 Å 
resolution but the anomalous signal measurability only extended to 10 Å. SAD phasing 
with Phaser failed to identify the location of any heavy atom sites. 
A1.3.2 Purification of PHOSPHO1 and PHOSPHO2 
 After changing the location of protein production to our laboratory, the hP1 
expression and purification protocol used in the Dunaway-Mariano laboratory could not 
be reproduced.  The objective of this section of research was to find an alternative 
method to express and purify sufficient hP1 protein to both reproduce previously 
obtained crystals and to solve the phase problem of previously collected datasets 
experimentally.  These methods have included the refolding of protein from inclusion 
bodies, additives during the lysis step of purification, various mutations, production of 
orthologous proteins, proteins with similar function, and transformation into various 
expression cell strains. 
 Cloning and expression of hP2 and gP2 proceeded concurrently with that of hP1 
and gP1 so that the substrate specificity, enzyme activity, and crystallization of the 
proteins could be addressed expediently.  The hP2 and gP2 genes were obtained and 
inserted into a Gateway plasmid for expression and purification testing, but faced many 
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of the same issues that appeared in the preparation of hP1. hP2 was produced in sufficient 
quantities for initial crystallization experiments and activity assays.  
 The activity of purified hP2 was measured using para-nitrophenylphosphate 
(pNPP) to verify correct expression and folding.  hP2 substrate activity was measured 
using a high-throughput phosphatase substrate screen (HTPS) developed in the Allen 
lab.(148) with activity observed for phosphoethanolamine, phosphocholine, 
phosphotyrosine, histidinolphosphate, glucosamine-6-phosphate and 2-deoxy-D-glucose-
6-phosphate.   
 To increase the likelihood of obtaining soluble protein, orthologues of 
PHOSPHO1 were identified in a number of other organisms.  The orthologue gP1 was 
selected as a suitable target on the basis of having a high enough sequence similarity 
(60%) to hP1 to be isofunctional but with enough of a difference in sequence that the 
expression and solubility of the protein may be different.  The codon optimized synthetic 
genes encoding orthologous gP1 and gP2 were purchased from Genewiz and went 
through expression testing in parallel with hP1 and hP2.  Low or no expression was 
observed with vectors containing tags (GST, MBP, SUMO) added to improve solubility 
of these constructs. 
 The expression of gP1 and gP2 was found to be minimal using the methods 
discussed earlier in this section and insufficient for enzyme activity or characterization 
studies.  Transformation of 502337 into Rosetta2 (DE3) cells was not successful but 
501217 and 501314 were able to be expressed and purified. Preliminary activity studies 
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of 501314 indicated that the protein was active and able to cleave phosphate from 
phosphoethanolamine. 
A1.3.3 Pre-Crystallization Optimization 
 Optimizing buffer selection through the use of a protein stability screen is 
important for obtaining a greater number of hits from initial sparse factorial 
crystallization screening.  Ensuring the optimum stability of the enzyme in the lowest 
concentration of buffer enhances the screening process by reducing the effect of the 
protein buffer in the crystallization conditions.  In addition, the increase in stability of the 
protein will benefit the yield during the purification process and storage of the purified 
protein.  The results of the melting temperature scan with the thermofluor indicated 
several buffers suitable for hP2 with a similar, but not significantly higher, temperature of 
unfolding when compared to the original purification buffer (Tris 7.5).  The stability of 
501314 in the buffers used showed a Tm of 42.3 °C for the original buffer solution of 50 
mM Hepes pH 7.5 and 100 mM NaCl. Thirteen different buffers produced a shift in Tm 
at least 1.0 °C greater than the original buffer. The buffer with the greatest increased in 
Tm, 44.5 °C, was 50 mM Tris pH 8.5, 100 mM NaCl, and 5% Glycerol. The next greatest 
increase in Tm, 44.1 °C, was 50 mM CHES pH 9.5, 100 mM NaCl, and 5% Glycerol. 
The next greatest increase in Tm, 44.0 °C, was 50 mM HEPES pH 7.5, 100 mM NaCl, 
and 5% Glycerol.  While these buffers do not result in a large Tm shift (usually a 4 °C 
shift is considered significant, they do indicate that 501314 is stable in the presence of 
NaCl and glycerol which could aid in purification. 
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A1.3.4 Crystalllization of hP2 
 Purified hP2 at a concentration of ~ 8mg/mL was subjected to crystallization 
screening using the Midwestern Structural Genomics Consortium (MSGC) suite of initial 
crystallization conditions.  The screening results showed that, 92% of the conditions had 
precipitate, with 14 of those conditions yielding microcrystals or crystals.  Screening 
indicated that 12 of those initial conditions were salt, while 2 did not diffract to a 
measureable level.  Those two conditions (35% MPD, Sodium/Potassium Phosphate 7.2, 
and 0.1 M Na2HPO4/KH2PO4 pH 6.2 35% (v/v) MPD) were optimized through additive 
screening (additive, silver bullet, silver bullet bio, detergent), grid screening and 
microseeding.  No diffracting crystals have yet been obtained, but additional 
crystallizations conditions remain to be explored.   
A1.3.5 Selenomethionine-substituted PHOSPHO2 
 A selenomethione derivative of PHOSPHO2 was prepared to experimentally 
determine phase information in data collection. This is the most commonly used 
technique for obtaining experimental phases and can be performed using protein 
expressed heterologously in bacterial cells.(104)  In order to obtain phase information 
from this technique, the protein must contain at least one methionine per 100 residues.  
PHOSPHO2 contains seven methionine residues out of 241 residues in total, making it 
suitable for phasing via selenomethionine incorporation.   PHOSPHO2 was expressed in 
M9 minimal media (suppresses methionine biosynthesis) with supplemental 
selenomethionine added but a contaminant at approximately half the molecular weight, 
possibly a truncated version of PHOSPHO2, was present in the purified sample, so 
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varying the expression condition (temperature, IPTG concentration, etc.) to promote 
more full length-PHOSPHO2 production and size exclusion chromatography to separate 
any truncation products will be used in the future to obtain protein for crystallization.  
A1.3.6 Homology Modeling of PHOSPHO1 
  To develop a understanding of how HAD members may generate substrate 
specificity the hP1, hP2, gP1, gP2, 501217, 501314 and 502337 structures have been 
modeled by threading the sequence of the protein onto a phosphatase homolog in the 
HAD superfamily, phosphoserine phosphatase (PSP) from Methanococcus jannaschii. 
While the sequence identity is low (19.4%), the two enzymes share a similar predicted 
secondary structure.(131)  Homologs with a higher sequence identity have not been 
identified to date, but a number of homology models with significant secondary structure 
identity have been constructed using the Phyre server (FigureA1.6).(99) The PSP crystal 
structure that serves as a basis for the homology model is in a conformation where the 
cap is protecting the active site. In addition to the type C1 cap insert, there is a β-hairpin 
specific to PSP inserted in the C2 location contributing to a less substrate-accessible 
environment around the active site than is found in type C1 or C2 alone.(146)   
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Figure A1.6. Phyre2 models of a) GP1 (purple) b) GP2 (blue) c) 501217 (red) d) 501314 (green) and e) 502337 
(orange).  
A1.4 Conclusions 
 While production of these eukaryotic HAD phosphatases remains challenging, 
progress has been made in better characterizing the phosphatases described in this 
section.  The 2.4 Å dataset of hP1 is still in need of phase information but as more models 
are added to the PDB, the chances of a suitable molecular replacement search model 
become more likely.  The described purification method of hP2 will be of use for further 
crystallization and activity study of the enzyme and could prove useful in the 
determination of its function.  As we gain a better understanding of the structural and 
functional characteristics of this group of phosphatases we make important strides 
towards understanding specificity within the HAD superfamily. 
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